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Abstract
This study evaluated the effect of a six-week deep slow breathing (DSB) program on
pain, physical function, and heart rate variability (HRV) in subjects with lower extremity joint
pain. Twenty subjects were assigned into training (n=10) and control (n=10) groups. The training
group participated in a six-week DSB program consisting of weekly training sessions and athome breathing exercises. DSB exercises focused on prolonging the exhalation and the pause
following exhalation. The Western Ontario and McMaster Osteoarthritis Index (WOMAC) was
used to assess pain and physical function and HRV data were obtained pre- and postintervention. Results revealed no significant interactions between group and time for any of the
variables. There was no significant main effect for group, but there was a significant main effect
(p < 0.025) and a large effect size for time on both pain (training pre 148 ± 94, post 84 ± 89;
control pre 123 ± 87, post 92 ± 73; group ηp2 = 0.003, time ηp2 = 0.454) and physical function
(training pre 434 ± 268, post 276 ± 287; control pre 482 ± 346, post 338 ± 274; group ηp2 =
0.010, time ηp2 = 0.506). There were no significant main effects (p > 0.017) for group and time
on LF power (training pre 179.30 ± 562.1 ms2, post 9.82 ± 28.84 ms2; control pre 32.08 ± 66.55
ms2, post 0.74 ± 0.73 ms2; group ηp2 = 0.039, time ηp2 = 0.061), HF power (training pre 14.04 ±
39.76 ms2, post 7.02 ± 19.24 ms2; control pre 7.43 ± 9.99 ms2, post 1.50 ± 1.87 ms2; group ηp2 =
0.039, time ηp2 = 0.039), and LF/HF ratio (training pre 5.64 ± 10.03, post 2.13 ± 3.72; control pre
2.38 ± 3.79, post 0.97 ± 0.69; group ηp2 = 0.036, time ηp2 = 0.169). Results indicated that the sixweek DSB program was not sufficient to alleviate pain or improve physical function in subjects
with lower extremity joint pain. As this is the first study to examine the use of DSB for lower
extremity joint pain and dysfunction, further research is needed to investigate the efficacy and
applicability of DSB.
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Chapter I
The Problem and Its Scope

Introduction
Arthritis is the leading cause of disability among adults in the United States, affecting an
estimated 50 percent of people age 65 and older. The disease costs the United States
approximately 128 billion dollars in medical care and lost wages annually and is associated with
other health disorders such as diabetes, hypertension, obesity, and cancer. Furthermore, half of
those with arthritis also suffer from cardiovascular disease (Centers for Disease Control and
Prevention (CDC), 2013), the leading cause of death among both men and women in the United
States (Centers for Disease Control and Prevention, 2011).
Osteoarthritis (OA) is the most common form of arthritis, mainly affecting the hands,
hips, and knees. Those suffering from OA experience a great deal of pain, limiting physical
activity and decreasing quality of life. Fear of pain or worsening symptoms may discourage
those with OA from beneficial exercise, leading to other health problems associated with OA
such as weight gain and heart disease (CDC, 2013). Intervention goals for OA include reducing
pain, improving quality of life, losing excess weight, and making lifestyle changes that improve
health such as diet and physical activity. Because pain is the major limiting factor for those with
OA, most interventions are aimed at reducing pain. However, surgical interventions are
expensive and non-surgical interventions, such as analgesics, physical therapy, and braces, have
low efficacy (Losina et al., 2014). Some interventions, such as pain relievers, may produce other
health complications, including damage to the liver, kidneys, and gastrointestinal (GI) tract (Max
& Stewart, 2008; Michael, Schlüter-Brust, & Eysel, 2010).

Clearly, there is a need for effective non-surgical interventions. Exercise has been
proposed as an effective and beneficial intervention for those with OA. Exercise reduces pain
and improves function, quality of life, mood, and confidence to manage health (CDC, 2013).
Despite the benefits of exercise, 60 percent of people suffering with the disease do not adhere to
physical activity guidelines and 23 percent are categorized as physically inactive (Austin, Qu, &
Shewchuk, 2012). This decrease in physical activity (hypokinesis) in those with OA may be a
result of pain or fear of worsening symptoms with exercise (Austin et al., 2012). Hypokinesis
progresses OA by increasing stiffness and weakness in the joints and causing metabolic acidosis
and chronic inflammation making exercise even more challenging (Michael et al., 2010).
Since aerobic and resistance training are effective non-surgical interventions but many
with OA will not participate, alternative exercises must be evaluated. Breathing exercises have
been used for years in a clinical setting to reduce pain and improve health, especially in labor and
delivery (Lothian, 2011). However, they have not been studied as an intervention for OA.
Respiration plays an important role in pain signaling and autonomic system activation, emotion
regulation, acid/base balance, and anti-inflammatory processes (Busch et al., 2012; Chalaye,
Goffaux, Lafrenaye, & Marchand, 2009; Jerath, Edry, Barnes, & Jerath, 2006; Nepal et al.,
2013). Recent studies suggest that deep slow breathing (DSB) relieves pain (Chalaye et al.,
2009) and improves mood (Busch et al., 2012). Studies in healthy subjects reveal that DSB
reduces pain by increasing pain threshold, increasing parasympathetic activity (Chalaye et al.,
2009), decreasing sympathetic activity (Busch et al., 2012), and altering pCO2 and pH (Chaitow,
Bradley, & Gilbert, 2014). Breathing also improves mood, which would largely impact those
with OA since many suffer from depression as well (Busch et al., 2012).
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Deep slow breathing has not been studied as an intervention for OA, but may be an
effective method for improving pain, function, and mood. This exercise model may be appealing
to patients with OA because the time commitment and cost are less than traditional therapeutic
measures. In addition, DSB puts no mechanical stress on the joints and may be relaxing for those
with OA. As symptoms improve with the use of DSB, those with OA may be more likely to
participate in other physical activities, resulting in further health benefits.

Purpose of the Study
The purpose of this study was to determine if a significant difference existed in joint pain
perception and heart rate variability (HRV) following a six week breathing exercise program.
The Western Ontario and McMaster Osteoarthritis Index (WOMAC) Visual Analog Scale (VAS)
is a valid measurement of pain, stiffness, and physical function for those with lower extremity
joint pain (Averbuch & Katzper, 2004; Ebrahimzadeh et al., 2014). Heart rate variability is
recognized as an indicator of autonomic nervous system (ANS) activity and assesses the balance
between parasympathetic (P-ANS) activity and sympathetic (S-ANS) activity (Malik et al.,
1996).
The goal of the breathing exercise program was to slow the breathing rate and increase
the pause following exhalation. These exercises may improve pain perception by increasing PANS activity and decreasing S-ANS activity (Chalaye et al., 2009). The breathing exercises may
also temporarily increase pCO2, resulting in enhanced buffering capacity and altered metabolic
acid/base homeokinesis. Respiratory and metabolic acid/base homeokinesis affect most
physiological processes, including pain and inflammation (Chaitow et al., 2014).
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Null Hypothesis
There will be no significant differences in WOMAC VAS pain and physical function
scores, heart rate variability (LF, HF, and sympathetic/vagal ratio), and expiratory pause at preand post-intervention between the training and control groups.

Significance
As the prevalence of OA rises, cost-effective interventions that target pain are highly
valuable in a clinical setting. The role of deep slow breathing (DSB) in improving chronic pain is
not well researched. Specifically, the effect of DSB has not been studied in patients with joint
pain. Results from this study will provide information about the role of DSB as an intervention
for joint pain. A better understanding of the effects and mechanisms of DSB may provide novel
and practical approaches to treating joint pain.

Limitations of the Study
1. Subjects with hip and/or knee joint pain were selected for this study. The results may not
be generalizable to those with pain in other joints.
2. All subjects kept a journal of breathing exercises at home, diet, daily physical activity,
and medications. Directly measuring these variables was not plausible for this study.
3. This study did not compare deep slow breathing to other modes of breathing or exercise
programs.

4

4. The breathing rate was not specified. The goal of the breathing exercises was to decrease
frequency and increase depth of breathing by increasing the expiratory pause from pre to
post intervention.
5. The trainer and subjects were not blinded in this study.
6. Control subjects did not attend weekly meetings. Training subjects may have benefited
from checking in with the researcher as well as group support.

Definition of Terms
Afferent fibers: A sensory fiber that carries impulses toward the central nervous system (Woolf
& Ma, 2007).
Arthritis: Painful inflammation and stiffness of the joints (Michael et al., 2010).
Central sensitization: Augmentation of responsiveness of central pain-signaling neurons to input
from low-threshold mechanoreceptors (Woolf & Ma, 2007).
Chronic pain: Pain that lasts longer than 12 weeks (Schaible, 2012).
Deep slow breathing (DSB): 6-7 breaths per minute (Busch et al., 2012; Chalaye et al., 2009).
End tidal carbon dioxide (ETCO2): The level of carbon dioxide in the air exhaled from the body.
Normal values are 4-6% or 35-45 mm Hg (Jonas, 2005). ETCO2 may be used as a
predictor of arterial partial pressure of carbon dioxide (PCO2) (Yosefy, Hay, Nasri,
Magen, & Reisin, 2004).
Expiratory pause: Holding the breath until the first urge to breathe following expiration (Chaitow
et al., 2014).
5

Forced expiratory volume (FEV1.0): The volume of air that can be forced out in one second, an
important measure of pulmonary function (Menezes et al., 2014).
Heart rate variability: The physiological phenomenon of variation in the time interval between
heartbeats. It is measured by the variation in the beat-to-beat interval (Malik et al., 1996).
High frequency (HF) power: power in the high frequency range of 0.15-0.4 Hz (Malik et al.,
1996). HF power is used as an indicator of parasympathetic activity (Chalaye et al.,
2009).
Hyperalgesia: Increased sensitivity to pain which may be caused by damage to nociceptors or
peripheral nerves (Woolf & Ma, 2007).
Hypothalamus: A region of the forebrain below the thalamus that coordinates both the autonomic
nervous system and the activity of the pituitary, controlling body temperature, thirst,
hunger, and other homeostatic systems, and involved in sleep and emotional activity
(Eckberg, Nerhed, & Wallin, 1985).
Inflammation: A protective tissue response to injury or destruction of tissues, which serves to
destroy, dilute, or wall off both the injurious agents and the injured tissue. The classical
signs of inflammation are pain, heat, redness, swelling, and loss of function (Li et al.,
2006).
Low frequency (LF) power: power in the low frequency range of 0.04-0.15 Hz (Malik et al.,
1996). LF power is used to indicate sympathetic activity (Chalaye et al., 2009).
Low to high frequency (LF/HF) ratio: The ratio between low and high frequency components of
heart rate variability represents sympatho-vagal balance (Malik et al., 1996).
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Metabolic acidosis: A pH imbalance in which the body has accumulated too much acid and does
not have enough bicarbonate to effectively neutralize the effects of the acid (Robergs,
Ghiasvand, & Parker, 2004).
Minute ventilation (VE): The volume of gas inhaled or exhaled from a person’s lungs per minute
(Cooper et al., 2003).
Neuropathic pain: Pain arising from disease or injury to the thermo-nociceptive component of
the nervous system at any level (Schaible, 2012).
Nociceptors: Sensory receptors that are preferentially sensitive to tissue trauma or a stimulus that
would damage tissue if prolonged (Woolf & Ma, 2007).
Osteoarthritis: A disease of the entire joint involving the cartilage, joint lining, ligaments, and
underlying bone (Michael et al., 2010).
Pain threshold: The point at which a stimulus, usually one associated with pressure or
temperature, activates pain receptors and produces a sensation of pain
(Chalaye et al., 2009).
Pain tolerance: The greatest level of pain which a patient is able to withstand
(Chalaye et al., 2009).
Parasympathetic autonomic nervous system (P-ANS): A branch of the autonomic nervous
system that slows heart rate, increases intestinal and glandular activity, and relaxes the
sphincter muscles (Eckberg et al., 1985).
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Peripheral sensitization: A lowering of the stimulus (pain) threshold for nociceptor activation and
an increase in the frequency of nerve impulse firing (hyperexcitability). Peripheral
sensitization can contribute to pain hypersensitivity found at the site of tissue
damage/inflammation (Woolf & Ma, 2007).
Power spectral density (PSD): provides the basic information of how power distributes as a
function of frequency (Malik et al., 1996).
Standard deviation of the NN intervals (SDNN): the square root of variance. SDNN reflects all
the cyclic components responsible for variability in the period of the heart rate variability
recording (Malik et al., 1996).
Sympathetic autonomic nervous system (S-ANS): A branch of the autonomic nervous system
that accelerates heart rate, constricts blood vessels, and raises blood pressure (Eckberg et
al., 1985).
Vagus nerve: The tenth pair of cranial nerves, supplying the heart, lungs, upper digestive tract,
and other organs of the chest and abdomen (Eckberg et al., 1985; Marek, Muckenhoff, &
Prabhakar, 2008).
Western Ontario and McMaster Universities Arthritis Index (WOMAC): The WOMAC is a
widely used, proprietary set of standardized questionnaires used by health professionals
to evaluate the condition of patients with osteoarthritis of the knee and hip, including
pain, stiffness, and physical functioning of the joints (Ebrahimzadeh et al., 2014).
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Chapter II
Review of Literature

Introduction
Osteoarthritis (OA) is a form of arthritis in which the proteins that make up the articular
cartilage begin to degrade. Repetitive stress on the joint leads to degeneration of the cartilage
causing pain, swelling, and stiffness. As OA progresses, the articular cartilage begins to flake or
form cracks. In advanced stages, the articular cartilage may be absent causing friction,
degradation of the bones, and stimulation of bone spurs resulting in more joint pain and swelling
(Michael et al., 2010). Since current non-surgical pain management approaches have low
efficacy (Losina et al., 2014), novel approaches are needed. It is difficult to treat OA pain
because the exact cause of OA pain is unknown. Pain is, however, related to autonomic nervous
system (ANS) activity and may be mediated by altering ANS activity (Busch et al., 2012;
Chalaye et al., 2009). Deep slow breathing (DSB) alters ANS activity and has been used for
years to reduce pain and improve health. DSB has not been studied as a method for relieving OA
pain, but may be a suitable intervention to improve pain, physical function, and mood (Busch et
al., 2012; Chalaye et al., 2009; Losina et al., 2014).

Etiology of Osteoarthritis
The exact cause of OA remains unknown, but it is likely due to an interplay between
systemic and local factors. The etiology involves both genetic and non-genetic factors (Felson,
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2004). Risk factors for developing OA include age, female gender, weight, ethnicity, joint injury,
repetitive overuse of the joint, low physical activity, low bone density, muscle weakness, joint
laxity, malformation, malposition, metabolic and endocrine disorders, alcohol and tobacco use,
and nerve injury (Michael et al., 2010). OA is also associated with other chronic diseases, such
as diabetes and heart disease. The relationship between OA and other diseases remains unclear,
but obesity and lack of physical activity are the main risk factors for developing these chronic
diseases (Michael et al., 2010).

Management of Osteoarthritis
Management of OA is important because pain related to this disease results in limited
physical function, decreased ability and willingness to exercise, and increased body fat, which
severely and negatively impact health and life expectancy. Because pain plays such an integral
role in the etiology of OA, the goal of most interventions is to reduce pain. Even though
interventions are aimed at decreasing pain, relatively few are successful and few prevent
progression of the disease. Some interventions, such as analgesics, are even harmful. Despite the
variety of interventions available to those with OA, Losina et al. (2014) report that over half of
people with knee OA will require a joint replacement during their lifetime. This demonstrates the
low efficacy of non-surgical interventions and the need for conservative and effective
management approaches.
Physical activity is recommended to reduce pain and improve function, mood, and body
composition (CDC, 2013). Exercise recommendations for patients with OA consist of 150
minutes of low impact, moderate intensity aerobic exercise per week combined with two days of
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resistance training. Even 60 minutes of moderate intensity exercise per week improves pain,
function, and health in those with OA (Lubar et al., 2010). Despite the benefits of exercise, most
people with OA do not meet these recommendations and many are physically inactive (Austin et
al., 2012). Pain and fear of worsening symptoms with exercise are reported as major barriers to
physical fitness (Lubar et al., 2010).
As a result of these barriers to exercise, more research is needed to identify novel and
non-invasive approaches to managing OA. Effective interventions must aim to reduce pain and
enable those with OA to make healthy lifestyle changes. Breathing techniques have been used
for years in a clinical setting to reduce pain and improve health, especially in labor and delivery
(Lothian, 2011). Respiration plays an important role in pain signaling, autonomic nervous system
activation, emotional regulation, acid/base balance, and anti-inflammatory processes.
Respiration’s involvement in many physiological processes as well as the brain’s ability to
consciously control breathing qualify it as a possible intervention for OA. Studies in healthy
subjects reveal that deep slow breathing (DSB) reduces pain by increasing pain threshold,
increasing parasympathetic activity (Chalaye et al., 2009), decreasing sympathetic activity
(Busch et al., 2012), and altering pCO2 and pH (Chaitow et al., 2014). DSB also improves mood,
which would help with depressive symptoms associated with OA (Busch et al., 2012).
DSB has not been studied as an intervention for OA, but may be an effective method for
improving pain, function, and mood. This exercise model may be appealing to patients with OA
because the time commitment and cost are less than traditional therapeutic measures. In addition,
DSB puts no mechanical stress on the joints and may be relaxing for those with OA. As
symptoms improve with the use of DSB, those with OA may be more likely to participate in
lifestyle changes, such as exercise, that provide further health benefits.
11

Measurement of Osteoarthritic Pain and Functional Limitation
To evaluate the effect of OA interventions, a valid and reliable measurement must be
used. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) is one of
the most commonly used self-reported measures of lower extremity symptoms and function. It
was specifically designed to evaluate pain, function, and stiffness in subjects with OA of the hip
and knee. The WOMAC has been studied for over 30 years in various contexts and in subjects of
different ethnic backgrounds. The WOMAC is supported as a valid and reliable measurement of
pain and function in subjects with hip or knee OA (Bellamy, Buchanan, Goldsmith, Campbell, &
Stitt, 1988; Dunbar, Robertsson, Ryd, & Lidgren, 2001; McConnell, Kolopack, & Davis, 2001;
Pua, Cowan, Wrigley, & Bennell, 2009; Wolfe & Kong, 1999).
The WOMAC is easy to use and minimal training is needed. The test takes about 12
minutes to administer. A copy of the WOMAC and a ruler for the visual analog scale (VAS)
version are the only equipment needed. Subjects use the VAS to answer 24 questions about pain,
function, and stiffness. The VAS is 100 mm long and uses anchors of no pain/stiffness/difficulty
to extreme pain/stiffness/difficulty. Subjects mark along the 100 mm continuum. A ruler is then
used to score the items. Items for each subscale are summed. Possible ranges for pain, stiffness,
and function are 0-500, 0-200, and 0-1700, respectively. Usually, total WOMAC score is
calculated by summing totals from each subscale. A higher score indicates worse pain, functional
limits, and stiffness (Bellamy, 2002).
The validity, reliability, and convenience of the WOMAC make it a good measurement
tool for studies regarding pain and function in those with hip and knee OA. For examination of
individual patients, determining the minimal meaningful change in WOMAC scores can be
challenging. The minimal clinically important improvement (MCII) value, defined as the
12

smallest change in measurement that indicates substantial improvement in symptoms, may be
used to determine the importance of WOMAC change scores. MCII values for hip and knee OA
are identified as -15.3 mm and -19.9 mm respectively, for pain, and -7.9 and -9.1 respectively,
for physical function (Tubach, 2005). This measurement tool may be applied to studies
examining the efficacy of pain interventions for hip and knee OA.

Neurophysiology of Osteoarthritic Pain
In order to understand the role of interventions in mitigating pain, it is imperative to
understand what causes pain and how it is processed. Despite the clinical importance of
understanding pain, there is surprisingly little research on pain compared with other health
conditions. This may partly explain the lack of effective interventions for the chronic pain
associated with OA.
Function of pain. Pain plays an integral role in protecting the body from damaging or
potentially damaging stimuli. Potentially damaging stimuli are detected by nociceptors: highly
specialized sensory receptors of the peripheral somatosensory nervous system. These receptors
detect noxious stimuli and send electrical signals to the central nervous system. Nociceptors are
located in the viscera, muscles, joints, meninges, and skin and are stimulated by mechanical,
chemical, or thermal stimuli. Nociceptors are the free nerve endings of primary afferent Aγ and
C fibers. Aγ fibers are small in diameter and lightly myelinated. Aγ fibers respond to mechanical
and thermal stimuli and result in fast, sharp pain. They are responsible for the reflex response to
acute pain. C fibers are the smallest of primary afferents and are unmyelinated. They have the
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slowest conduction and respond to chemical, mechanical, and thermal stimuli. Activation of C
fibers results in chronic, slow, burning pain (Woolf & Ma, 2007).
Upon activation, primary afferent fibers synapse with secondary afferent neurons in the
dorsal horn of the spinal cord and information is sent to the higher centers in the brain. There are
two main pathways by which these signals are sent: the spinothalamic tract and the spinoreticular
tract. In the spinothalamic tract, secondary afferents ascend in the contralateral spinothalamic
tract to nuclei within the thalamus. Third order neurons then ascend to the somatosensory cortex
or the periaqueductal grey matter (PAG). In the spinoreticular tract, fibers ascend the
contralateral cord to reach the brainstem reticular formation. Then, they are projected to the
thalamus and hypothalamus. There are many further projections to the cortex. The spinothalamic
tract transmits signals that are important for pain localization and the spinoreticular tract is
involved in emotional aspects of pain (Schaible, 2012; Sofat, Ejindu, & Kiely, 2011; Woolf &
Ma, 2007).
Once the noxious signal reaches the brain, it is processed by the higher brain centers.
Pain is highly individualized and subjective, making it difficult to study. It is affected by mood,
beliefs, genetics, and cognition (Max & Stewart, 2008; Rainville, 2002; Tracey & Mantyh, 2007;
Wiech, Ploner, & Tracey, 2008; Wiech & Tracey, 2009). Studies using functional magnetic
resonance imaging (fMRI) show that a large brain network is stimulated when pain is perceived.
The most commonly activated brain regions include the primary and secondary somatosensory
(S1 and S2) cortices, insular cortex, anterior midcingulate cortex, posterior cingulate cortex,
orbitofrontal cortex, prefrontal cortex, and the thalamus. Studies evaluating the validity of pain
scales suggest that rated pain directly corresponds to brain activity, supporting the argument that
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pain is highly individualized. Some experience noxious stimuli more intensely than others. These
brain regions must play an important role in pain processing (Kulkarni et al., 2007).
It is clear that the pain pathways are activated during OA, but what causes the associated
pain to begin and why does it persist? Since the exact cause of OA is unknown, it is difficult to
answer these questions. In many cases, OA is probably due to a combination of mechanical
stress and humoral factors released by adipose tissues. These factors result in damage to the
articular cartilage and surrounding joint tissues. The damaged tissues release protons and other
inflammatory mediators, causing inflammation, lowering local pH, and resulting in sensitization
of the nociceptor (Sofat et al., 2011).
Peripheral sensitization. Normally, the pain threshold is high and only stimuli that are
actually or potentially damaging are detected. In OA, acidosis and inflammation cause
depolarization and sensitization of the nociceptors. Sensitization decreases the threshold and
increases responsiveness of the nociceptors to non-noxious stimuli. Some of the sensitizers
present with OA are kinins, amines, prostanoids, growth factors, chemokines, cytokines, protons,
and adenosine triphosphate (ATP) (Woolf & Ma, 2007). These sensitizers work by binding to
their specific receptor on the nociceptor membrane. This binding occurs as a result of activation
of intracellular signal transduction pathways (Doya et al., 2005; Hucho, 2005; Jin & Gereau,
2006; Malik-Hall, Dina, & Levine, 2005; Mizushima et al., 2007; Varga et al., 2006). Other
effectors include phosphorylation of transient receptor potential (TRP) and voltage-gated sodium
channels which alter thresholds and kinetics (Woolf & Ma, 2007).
Sensitization results in a heightened state of sensitivity. Stimuli that are normally
innocuous may be detected as noxious stimuli. Heightened pain sensitivity can be beneficial by
reducing use of or contact with the injured joint. However, persistent changes in nociceptor
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function are pathological and contribute to OA pain. Typically, restoration of the nociceptor to
normal function would suffice. With OA, this does not work because the inflammation will still
be present and drive the depolarization of these sensory neurons. In advanced stages of OA,
chronic pain when no stimulus seems to be present may be explained by sensitization. With a
reduced threshold, normal body temperature or blood vessel pulsation may stimulate low
threshold nociceptors and result in pain (Woolf & Ma, 2007).
Central sensitization. In addition to peripheral sensitization by localized noxious
stimuli, structural and biochemical changes may also occur in the systems that perceive pain
(Sofat et al., 2011). Pathological input from the joint may cause complex changes in the central
nervous system, known as central sensitization. With central sensitization, nociceptive neurons
become hyperexcitable and the processing of noxious stimuli is amplified. Central sensitization
has both spinal and supraspinal components (Schaible et al., 2009). Central sensitization is seen
in advanced stages of OA. Methods of this sensitization remain unknown and are difficult to
study (Schaible, 2012).
Acid-sensing ion channels. Protons which are involved in sensitization may also be
detected by acid-sensing ion channels (ASICs). These protons are released by damaged tissue
and decrease the pH in the joint. This change in pH is detected by ASICs, which may function as
a specific type of nociceptor. It is unknown whether ASICs transduce or mediate noxious stimuli.
However, since ASICs are highly sensitive to pH, they are considered to be closely linked with
pain processing (Voilley, 2004).
Local pH often drops below 7 with inflammation, infection, ischemia, and exercise
(Goldie & Nachemson, 1969; Rehncrona, 1985). This dramatic change is detected by ASICs and
a signal is sent to the brain. ASIC expression and currents are increased with experimentally
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induced inflammation in the rodent paw (Voilley, de Weille, Mamet, & Lazdunski, 2001) and the
mouse knee (Masahiko Ikeuchi, Kolker, & Sluka, 2009; M. Ikeuchi, Kolker, Burnes, Walder, &
Sluka, 2008). This supports the hypothesis that ASICs have a nociceptive function. ASICs may
be related to neuropathic pain. Compression of the spinal nerve root causes both hyperalgesia
and increased expression of ASIC3 (Ohtori et al., 2006). This suggests a potential mechanism for
neuropathic pain. Ivanavicius et al. (2007) suggest that OA pain has a neuropathic component.
Neuropathic pain. Neuropathic pain is non-nociceptive and initiated by a lesion or
dysfunction of the nervous system. Pain caused by the nerve injury could be a result of both
peripheral and central sensitization in combination with local inflammation. Studies using the
monoiodoacetate (MIA) pain model support the theory that OA pain may be partially due to
neuropathy (Ivanavicius et al., 2007; Orita et al., 2011). In this model, MIA is injected into the
joint and arthritis symptoms develop rapidly, unlike actual OA. MIA blocks glycolysis and is
toxic for chondrocytes. Twenty four hours post-injection, chondrocytes shrink, fragmented
pyknotic nuclei appear, synovial membrane is expanded by fibrin proteinaceous edema fluid, and
the joint is invaded by lymphocytes, macrophages, and plasma cells. Days later, the
inflammatory response in the synovium subsides, necrotic cartilage collapses, and chondrocytes
are lost. Osteoclastic activity is increased, subchondral bone collapses, and fragmentation of
bone trabeculae are surrounded by osteoclasts and some replacement by fibrous tissue and newly
laid trabecular bone appear (Schaible, 2012). With MIA injection, a high number of neurons in
the dorsal root ganglia (DRG) express ATF-3 immunoreactivity, suggesting neuropathic pain
(Ivanavicius et al., 2007; Orita et al., 2011). Furthermore, upregulation of galanin and
neuropeptide Y, downregulation of substance P and CGRP in DRG neurons (Im et al., 2010),
and activation of spinal microglia (Orita et al., 2011) were found. Similar differences were seen
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with a surgical model (Orita et al., 2011). In a study by Ivanavicius et al. (2007), rats with OA
showed increased sensitivity to gabapentin, a molecule used to treat neuropathic pain in humans.
These studies provide further evidence for a neuropathic component in OA pain.
Central pain processing. In addition to these mechanisms, neuroimaging studies,
including functional magnetic resonance imaging (fMRI) and positron emission tomography
(PET) scans, have revealed that structure and activity of pain processing brain regions are altered
with OA. Baliki et al. (2008) measured brain activity in response to noxious mechanical knee
stimulation in subjects with knee OA. Results showed that noxious knee stimulation was
associated with bilateral activity in the thalamus, secondary somatosensory, insular, and
cingulate cortices, and unilateral activity in the putamen and amygdala. Local lidocaine treatment
of the knee reduced brain activity seen on fMRI for these regions.
Kulkarni et al. (2007) used PET and compared brain activity between patients with
arthritic knee pain, experimental knee pain, and no pain. With arthritic pain, regional cerebral
metabolic rate for glucose (rCMRGlu) was bilaterally enhanced in all areas of the brain involved
in pain processing: posterior cingulate cortex, anterior midcingulate cortex, prefrontal cortex,
orbitofrontal cortex, and primary somatosensory cortex. Unilateral activations were seen in the
thalamus, anterior perigenual cingulate cortex, amygdala, and supplementary motor area. The
most statistically significant activity observed with arthritic pain was in the anterior cingulate
cortex, although activation spanned from anterior to posterior midcingulate region (Kulkarni et
al., 2007). The cingulate cortex is a fundamental part of the limbic system and appears to play an
important role in the emotional processing of pain perception (Price, 2000).
Interestingly, when arthritic and experimental pain were compared, arthritic pain was the
only pain associated with increased activation of the limbic system, involved in affect, aversive
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conditioning, and motivation. This may explain why many people with OA also suffer from
anxiety, depression, and other psychological disturbances. In addition to over-activation of pain
processing centers, those with OA exhibit atrophy of the thalamus (Kulkarni et al., 2007) and the
gray matter of pain-related cortical areas (Hess et al., 2011). These atrophies were reversible
after arthroplasty suggesting that atrophy is more likely a side effect than a cause (RodriguezRaecke, Niemeier, Ihle, Ruether, & May, 2009).
Descending pathways. Descending neural pathways may also contribute to OA pain.
Neural pathways descending from the brainstem play an important role in balancing inhibition
and facilitation of nociception. The diffuse noxious inhibitory control (DNIC) is a form of
inhibition that is dysfunctional in those with severe OA. Function is restored following joint
replacement. Other studies reveal that with OA, serotoninergic descending facilitation (Rahman
et al., 2009), as well as increased activation of the periaqueductal gray (PAG) in the brain stem
(Gwilym et al., 2009) play a role in OA pain. These studies suggest that an imbalance between
inhibitory and excitatory descending systems could play a role in OA pain generation (Schaible,
2012).
Autonomic nervous system activity. The ANS plays an important role in homeostasis
and adaptive responses to stress, including pain (Cortelli, Giannini, Favoni, Cevoli, & Pierangeli,
2013). The parasympathetic ANS (P-ANS) and the sympathetic ANS (S-ANS) are both involved
in pain perception and regulation. In chronic pain, the balance between P-ANS and S-ANS
activity becomes disturbed. Specifically, P-ANS activity decreases and S-ANS activity increases
(Dowling, 1982, 1983; Tracy et al., 2015). Heart rate variability (HRV) is often used to assess
ANS activity. High frequency (HF) power is used to denote parasympathetic activity and low
frequency (LF) power is used to denote sympathetic activity, although LF power may more
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accurately indicate a combination of parasympathetic and sympathetic activity (Chalaye et al.,
2009).
In studies of subjects with chronic pain, increased pain was associated with decreases in
HF power and LF/HF ratio and increases in LF power, confirming a decrease in parasympathetic
activity and an increase in sympathetic activity with chronic pain (Busch et al., 2012; Chalaye et
al., 2009; Fischer et al., 2015; Tracy et al., 2015). The relationship between pain and ANS
activity is also substantiated by the positive correlation between pain and cortisol levels (Fischer
et al., 2015; Goodin et al., 2012) and the positive correlation between pain and skin conductance
levels (Busch et al., 2012; Loggia, Juneau, & Bushnell, 2011). Increased cortisol levels and
increased skin conductance levels are both indicative of greater S-ANS activity (Busch et al.,
2012; Goodin et al., 2012; Loggia et al., 2011). The role of the ANS in responding to and
mediating pain may be important in understanding and targeting chronic pain.
Targeting osteoarthritic pain. Treating OA pain is difficult since the origin and cause of
pain are not yet elucidated. Further research on pain mechanisms and pathways will help provide
more effective management options for those suffering with OA. Currently, most pain therapies
aim to block nociception or neutralize cytokines and inflammatory factors involved in
nociception. This is problematic for a number of reasons. It is important that normal nociception
is maintained with these interventions to protect the body from undetected tissue damage
(Schaible, 2012). Additionally, there will always be more inflammatory mediators readily
available to sensitize the nociceptor, causing pain and further damage in those with OA. To date,
one medication cannot target all sensitizers (Woolf & Ma, 2007). An intervention that targets the
source of pain and the pathways involved rather than the signal produced may be more effective
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for those suffering with OA. Breathing may be a suitable alternative approach that targets local
and systemic factors involved in pain processing.

Deep Slow Breathing to Improve Osteoarthritic Pain
Deep slow breathing (DSB) is often used in a clinical setting to relieve pain or improve
health. Practices that utilize DSB include Lamaze (Lothian, 2011), yoga (Sovik, 2000), qi-gong
(Li & Yeh, 2005), pranayama (Singh, Malhotra, Singh, Madhu, & Tandon, 2004), tai chi (J. X.
Li, Hong, & Chan, 2001), relaxation (Chalaye et al., 2009) and Buteyko breathing (Chaitow et
al., 2014). Despite the widespread use of DSB, there are relatively few studies examining the
effect of deep breathing as an analgesic (Chalaye et al., 2009). Specifically, there is currently no
research examining the use of DSB as an analgesic for osteoarthritis. Most research on DSB and
pain is conducted using healthy subjects or those with cardiovascular disease. This research
suggests that there is a strong relationship between autonomic activity and pain perception. It is
proposed that DSB functionally resets the autonomic nervous system and synchronizes neural
function in the heart, lungs, limbic system, and cortex (Jerath et al., 2006). In a study by
Chambers, Taddio, Uman, and McMurtry (2009), breathing exercises significantly reduced pain
reported by children during immunizations and distress observed by parents or nurses. A few
studies have examined possible mechanisms of DSB in providing pain relief (Busch et al., 2012;
Chalaye et al., 2009; Jerath et al., 2006).
Altered pain threshold. DSB may decrease pain by increasing the pain threshold of
nociceptors. Chalaye et al. (2009) examined the effect of DSB on experimental heat pain and
autonomic cardiac activity. They compared natural breathing to DSB (six breaths per minute),
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rapid breathing (16 breaths per minute), breathing with a distraction (playing a video game), and
a biofeedback control where subjects synchronized their breathing and heart rate. Respiratory
rate and depth were measured with a piezo-electric respiratory belt transducer.
Chalaye et al. (2009) hypothesized that DSB and heart rate (HR) biofeedback would
produce the strongest analgesic effects and greatest cardiac changes. Results revealed significant
differences between the groups for thermal pain threshold and tolerance. Mean pain threshold
values significantly increased from baseline following HR biofeedback (+1.6° C, p<0.005), DSB
(+1.0° C, p<0.05), and breathing with a distraction (+1.1° C, p<0.05). Mean pain tolerance
values significantly increased following HR biofeedback (+0.7° C, p<0.005) and DSB (+0.5° C,
p<0.005). Contrariwise, rapid breathing was followed by a decrease in pain threshold (-0.2° C)
and no change in pain tolerance although these results were not statistically significant.
DSB and HR biofeedback had the largest impact on pain thresholds and tolerances. DSB
had an analgesic effect whether it was done before or after rapid breathing. Rapid breathing had
no analgesic effect regardless of the order in which the subject completed the different breathing
conditions. In this study, the intensity range from pain threshold to pain tolerance was only 3.3
degrees Celsius. Average changes in thermal pain thresholds were about 1 degree Celsius higher.
This may seem unimportant, but when considering the exponential function linking temperature
and pain, a one degree increase will produce great changes in perceived pain (Chalaye et al.,
2009).
Similarly, Busch et al. (2012) examined the effects of DSB on pain perception and
sympathetic arousal in 15 healthy subjects. They specifically examined the difference between
attentive versus relaxed DSB. The methods of breathing were similar for both groups. The
attentive DSB (aDSB) subjects breathed according to a respiratory feedback task. They were
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presented with an ideal breathing curve including frequency and depth. Their own breathing
curve was simultaneously shown to them on a screen with the ideal curve. They were asked to
match their breathing with the ideal curve, requiring their attention and concentration.
The relaxed DSB (rDSB) subjects were told to concentrate on the experience of
breathing. They received verbal instruction during the experiment in order to keep respiration
rates similar to the aDSB condition. The rDSB condition was more similar to a meditative state
and required little cognitive processing. A respiration rate of 7 cycles per minute (cpm) was used
for both groups. The ratio of expiration/inspiration/pause was 60/30/10 (Busch et al., 2012), as
suggested by previous literature (Cappo & Holmes, 1984; Strauss-Blasche et al., 2000).
Busch et al. found a significant increase in pain thresholds of subjects after only three
microcycles of rDSB. aDSB did not alter pain thresholds suggesting that relaxation is an
important part of DSB. This is supported by other research that suggests DSB may reduce pain
intensity rating compared with rapid breathing (Grant & Rainville, 2009). This study was not
able to demonstrate a difference between relaxation and deep breathing, but they lacked a control
group. This actually supports the claim that relaxation is an essential component of pain
perception attenuation. The argument could be made that aDSB is more distracting than rDSB,
but Busch et al. counter this by arguing that some individuals may be just as distracted by
concentrating on certain distracting thoughts during rDSB, just as some may be distracted by
matching their curve to the ideal respiratory curve.
Sympathetic nervous system activity. DSB may decrease pain by altering autonomic
nervous system activity. Busch et al. (2012) measured sympathetic activity by measuring skin
conductance levels (SCLs). Results showed significant decreases in SCL in all cycles during the
rDSB condition, signifying slowing of sympathetic activity. Pain thresholds and SCLs were
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inversely correlated for rDSB. The inverse correlation suggests that sympathetic activity plays an
important role in pain perception. Slowing of the sympathetic system may mediate pain. Other
studies report that basal electrodermal activity is significantly reduced during meditation (Travis,
2001), mindfulness-based stress reduction (Lush et al., 2009), or integrative body-mind training
(Tang et al., 2009).
Alternatively, aDSB increased sympathetic arousal. Other studies corroborate this
finding. Cappo & Holmes (1984) found that challenging breathing exercises increased
sympathetic arousal. Furthermore, a study of subjects with high trait anxiety characteristics
revealed that rDSB without concentration on a pacing tone had a greater reduction of SCL
compared with aDSB. The increase in SCL seen with aDSB in this study was associated with
increased anxiety and muscle pain (Ozgocmen, Ozyurt, Sogut, & Akyol, 2006). Decreased
sympathetic arousal and pain perception in response to DSB may be a result of downregulation
in stress activity (Craig, 2003). This may be due to increased vagal tone and parasympathetic
nervous system activity (Chalaye et al., 2009; Chandla et al., 2013).
Vagal tone and parasympathetic nervous system activity. Increased vagal activity is
hypothesized to decrease pain perception. The vagus nerve is the tenth cranial nerve, nuclei
located in the medulla oblongata. The vagus nerve constitutes an important part of the
parasympathetic autonomic nervous system. The vagus nerve is connected to regions of the brain
controlling the autonomic nervous system, emotions, memory, and social behaviors (Snell,
2001). Homeostasis of most of the body's systems that operate on a subconscious level is
regulated by the vagus nerve. Vagal activity is usually continuous and passive and is used an
indicator of parasympathetic nervous system activity. Vagal tone cannot be directly measured so
other measures are used to represent vagal activity. Increased vagal tone slows the heart rate and
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increases heart rate variability. Respiratory sinus arrhythmia (RSA) is a variation in heart rate
during the breathing cycle. During RSA, inhalation restrains vagal activity which increases heart
rate. Exhalation causes heart rate to decrease and vagal activity to resume. Since vagal tone
cannot be directly measured, heart rate variability (HRV) is used to denote vagal activity
(Chalaye et al., 2009).
Vagal activity is directly related to breathing. During inspiration, stretch receptors in the
lungs are stimulated. This produces a signal which is carried by vagal type C fibers through the
nucleus tractus solitarius (NTS) to the hypothalamus. It is hypothesized that different impulse
patterns produced by the vagus nerve during breathing affect the hypothalamus which controls
autonomic balance. Increased vagal activity also inhibits the sympathetic vasomotor area in the
medulla and may affect other brainstem and medullary nuclei that influence autonomic activity
(Ganong, 2005). Corticospinal tracts controlling respiration also affect autonomic activity (Snell,
2001). These circuits may work together to decrease sympathetic activity and increase
parasympathetic activity (Chandla et al., 2013).
The hypothesis that DSB increases vagal activity is supported by the findings of Chalaye
et al. (2009). Mean standard deviation of the N-N interval (SDNN) was used as a general
measure of HRV and the peak-to-valley index was used to measure breathing-induced
oscillations in heart rate (HR) which is dependent on efferent vagal activity. Mean SDNN values
rose significantly from baseline (52.1 ms) to 99.8 ms (p<0.05) following DSB and to 96.4 ms
(p<0.05) following HR biofeedback. SDNN values decreased following rapid breathing and
distraction conditions although results for these conditions were not statistically significant.
Mean peak-to-valley amplitudes increased from baseline (0.099, p<0.05) following DSB (0.296,
p <0.05) and HR biofeedback (0.288, p<0.05). Rapid breathing and distraction conditions
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resulted in decreased peak-to-valley amplitudes. The rise in SDNN and peak-to-valley amplitude
following DSB and HR biofeedback conditions indicate increased vagal activity.
HF power is another measure of vagal activity. HF power was not significantly altered
with any of the breathing conditions. Counterintuitively, LF power increased significantly from
baseline (1,524 ms2) to 9,194 ms2 (p<0.05) following DSB and 8,463 ms2 (p<0.05) following HR
biofeedback (Chalaye et al., 2009). The interpretation of LF is often disputed. While some
consider LF power a measure of sympathetic activity, others consider LF power a measure of
both sympathetic and vagal activity. Some suggest that as total power spectral density (PSD)
increases, both LF and HF may increase (Malik et al., 1996). Chalaye et al. (2009) suggest that
LF power increased with DSB and HR biofeedback as a result of overlap of RSA-associated
oscillations and slow HR oscillations. Research is somewhat unclear on the interpretation of LF
power relating to autonomic activity.
Chandla et al. (2012) also evaluated the effects of DSB by examining the use of
pranayama, a word meaning "extension of the prana or breath." Previous studies revealed that
practicing slow breathing pranayama for three months resulted in increased parasympathetic
activity and decreased sympathetic activity (Pal, Velkumary, & Madanmohan, 2004). Chandla et
al. found that six weeks of slow breathing increased vagal parasympathetic tone. This was seen
in the decrease in LF from baseline (76.93 nu) to 50.88 nu (p<0.001) and the increase in HF from
baseline (49.26 nu) to 64.60 nu (p<0.001) following six weeks of pranayama. The LF/HF (power
%) ratio also decreased from 4.67 (baseline) to 1.58 (p<0.001). These findings are much clearer,
suggesting decreased sympathetic activity and increased vagal activity. Pal et al. reported similar
findings in increased vagal tone after DSB exercises. Snell (2001) reported that DSB also
increased thoracic pressure, venous return, and systolic blood pressure. Changes in blood
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pressure are sensed by baroreceptors that send signals to the NTS. The NTS then sends
excitatory signals to the nucleus ambiguous which control parasympathetic activity. The NTS is
connected with the lateral parabrachial nucleus, ventrolateral medulla, and PAG, and involved in
nociception (S. Telles & Desiraju, 1991). Activation of the baroreceptors also produces
excitatory effects on NTS pain inhibitory relays (Ganong, 2005).
Autonomic alterations due to tissue oxygenation. Although autonomic nervous system
alterations in response to DSB are seemingly due to increased vagal tone, some studies suggest
that changes are due to increased tissue oxygenation. However, there is currently little research
to support this claim. Increased tissue oxygenation was seen with DSB, but not with rapid
breathing. Researchers suggest that this increase in oxygenation with DSB could explain
alterations in autonomic function (Pal et al., 2004; S. Telles & Desiraju, 1991). In addition,
pranayama reduced oxygen consumption per unit work with time (Raju et al., 1994) and reduced
oxidative stress levels. Increased superoxide dismutase levels and a decrease in the number of
free radicals were also observed with pranayama practice. These results have long-term benefits
and may explain the cardiopulmonary benefits associated with pranayama (Bhattacharya,
Pandey, & Verma, 2002). In a study of Himalayan high altitude subjects, deep breathing
exercises increased arterial oxygen saturation irrespective of age, gender, or altitude. However,
the results of this research are questionable since raw data is only given for hematocrit levels
(Nepal et al., 2013). Although the research on this aspect of DSB is limited, this may be an
important part of how DSB influences the autonomic nervous system and reduces pain.
Pulmonary function, carbon dioxide and pH. DSB may alter acid/base balance in the
body by improving buffering capacity and pulmonary function. Buteyko breathing is a special
form of DSB, based on the theories of Dr. Konstantin Buteyko. Buteyko hypothesizes that many
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chronic diseases result from hyperventilation, resulting in carbon dioxide deficiency and
metabolic disequilibria. Carbon dioxide is important for many physiological functions such as
maintaining acid/base balance, dissociation of oxygen, and many chemical reactions. Buteyko
breathing techniques include reduced-volume breathing, slow breathing, breath-holding
techniques, and nasal breathing. Emphasis is put on the expiration phase of respiration and
breath-holding pauses following expiration (Chaitow et al., 2014).
Buteyko theorizes that deep slow breathing followed by a pause increases carbon dioxide
in the blood and enhances the body’s buffering capacity. This, in turn, affects pH which is
related to chronic diseases such as OA (Chaitow et al., 2014). This theory is supported by
research demonstrating that the expiratory pause decreases minute ventilation which corresponds
with carbon dioxide concentration in the alveolar air (Cooper et al., 2003). In addition, Buteyko
breathing may increase forced expiratory volume (FEV1.0), a predictor of mortality (Menezes et
al., 2014) and morbidity (Varela et al., 2007).
Buteyko breathing has mainly been studied in those with pulmonary diseases and has not
been studied in OA. Despite the lack of research on Buteyko breathing as an intervention for
diseases such as OA, parts of this model may be incorporated into a breathing program for those
with OA. The emphasis on expiration and the pause following expiration may be beneficial for
improving buffering capacity which alters pain perception (Chaitow et al., 2014).

Summary
Although there is no research examining the effects of DSB as an intervention for OA,
evidence suggests that DSB would be beneficial and effective. It is likely that DSB would
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alleviate OA pain by increasing the pain threshold, altering autonomic activity, increasing
oxygen saturation, decreasing reactive oxygen species involved in pain signaling, and altering
acid/base metabolism (Busch et al., 2012; Chaitow et al., 2014; Nepal et al., 2013).
Further research is needed in order to examine the effects of DSB on pain and
functionality in those with OA. The WOMAC may be used to evaluate changes in pain and
functional limits in subjects with hip or knee OA following DSB training (Bellamy et al., 1988).
Results from this research may provide novel OA management approaches that are cost effective
and easy to complete.
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Chapter III
Methods and Procedures
Introduction
This study was designed to examine the effect of a six week deep slow breathing (DSB)
program on pain perception and heart rate variability (HRV) in subjects with lower extremity
joint pain. This study provided information about the role of breathing in the management of
joint pain. Novel and non-invasive management for joint pain is needed to decrease pain and
improve function in those suffering from the disease.

Description of Study Population
Twenty subjects participated in the study. Subjects had been diagnosed by their physician
with lower extremity osteoarthritis (OA) or had received a normative score of less than 50 on the
American Academy of Orthopaedic Surgeons (AAOS) Hip and Knee Questionnaire. Subjects
were recruited from the Bellingham Senior Activity Center and Western Washington University
in Bellingham, WA and the Blaine Senior Center in Blaine, WA, following approval of the study
from the University Human Subjects' Committee. Posters with information about the study were
displayed at the senior centers and in the monthly newsletters, and sent directly to university
students who knew the primary researcher and were interested in participating in the study.
Subjects with unilateral joint pain had no history of joint replacement surgery. Subjects with
bilateral joint pain that had undergone joint replacement surgery on only one joint were allowed
to participate in the study. The joint that had not been operated on was used for assessment with
the WOMAC. For subjects with bilateral joint pain that had not undergone joint replacement
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surgery, the extremity with more severe pain, determined by the WOMAC pain score, was used
for WOMAC assessment. No subjects had undergone joint surgery within the last six months.
All subjects obtained medical clearance from a physician to participate in the study.

Design of the Study
This study utilized a pretest-posttest experimental design in which subjects were assigned
to either the control or training group based on their availability for training. Those who could
meet the time commitment for the training group were assigned to the training group on a first
come first serve basis.

Instrumentation
Heart rate variability (HRV) was measured using Biopac Systems MP1500 (Goleta, CA).
Disposable adhesive electrodes were used for the subject-EKG interface and HRV measurements
were taken with a standard 3-electrode, 1-lead EKG setup which examined lead II. A MP1500
(BIOPAC Systems Inc., Goleta, CA) interfaced with a Pentium III computer was used.
AcqKnowledge software (BIOPAC Systems Inc., Goleta, CA) was used for data recording,
collection, and data reduction.
The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Visual
Analog Scale (VAS) was used to measure pain and physical function before and after the study.
Nutritionist Pro software (Redmond, WA) was used to measure caloric intake and the Bouchard
method was used to determine energy expenditure (Bouchard et al., 1983) before and after the
study.
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Experimental Protocol
Training protocol for all subjects. The study was conducted over a six week period. All
subjects were instructed not to alter their diet or physical activity level during the study. Three
day diet and three day physical activity logs were completed pre and post breathing intervention.
These logs were used to verify that no substantial changes were made in diet or physical activity.
A medication log was submitted before and after the study. Subjects were instructed to notify the
instructor if they began a new pain medication during the course of the six week DSB training. If
a subject began a new pain medication during the study, they were excluded from the study. The
control group did not attend weekly breathing training sessions.
Weekly breathing training. Breathing training took place at the Bellingham Senior
Activity Center in Bellingham, WA. Subjects were instructed to wear comfortable and loose
fitting clothes Weekly sessions lasted for 30 minutes. Subjects were divided into groups of 2-4
subjects. During DSB training, all subjects sat upright on a chair with back support. Subjects
were informed of the discomfort or “air hunger” they may experience during DSB training.
Subjects were assured that they could take a break from the breathing exercises if they felt dizzy
or out of breath.
During the first twenty minutes of breathing training, a script or outline was used to guide
subjects through the breathing exercises. A script was used during the first week and outlines
were used for the remaining weeks so that the trainer could more easily monitor the subjects. The
script and outlines were timed and all subjects received the same training. The main focus of the
breathing exercises was on inhaling deeply, prolonging the exhalation, and performing the
expiratory pause. Each week, subjects were given a focus topic in order to keep their interest in
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the program. Weeks one and two focused on awareness of breathing, weeks three and four
focused on relaxation and tension release, and weeks five and six focused on breathing control.
Specific parameters for controlling depth and frequency of breathing were not used in
this study. The goal of the breathing exercises was to increase the depth and decrease the
frequency of respiration from initial values for each individual. The expiratory pause aided
subjects in reducing breath frequency. The remaining ten minutes of training was used to record
respiratory rate and expiratory pause for each subject.
Respiratory rate was measured by counting the number of times the chest or abdomen
inflated and deflated in one minute. Subjects performed the expiratory pause following normal
inhalation and exhalation. Following exhalation, subjects plugged their nose with their fingers
and closed their mouth. This was held until the subject felt the very first urge to inhale. The
amount of time that a subject could hold this pause was recorded as the expiratory pause
(Chaitow et al., 2014). The data obtained were used for developing the training program and
were not used for biofeedback.
At-home breathing protocol. DSB subjects were instructed to complete the DSB
exercises with the expiratory pause at home five days a week, 20-30 minutes a day (Chaitow et
al., 2014). DSB subjects were given written instructions and a link to an instructional YouTube
video on the expiratory pause (see appendix) to help them practice during the week. DSB
subjects were educated on the importance of relaxation during DSB and instructed not to
complete the breathing exercises while doing an attentive task such as reading, watching TV,
conversing with family, or other tasks. Subjects were instructed to do the breathing exercises in a
quiet room in an upright, seated position on a chair with back support. Both feet were to be
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placed on the floor. On the day of the weekly group training session, subjects were not required
to complete additional DSB at home.
If subjects missed a weekly training session at the Bellingham Senior Center, they were
required to make up the session on another day with the trainer. Subjects kept a breathing log and
returned the log to the trainer each week to ensure compliance with the study.

Measurement Techniques and Procedures
The WOMAC was used to measure pain (five items) and physical function (17 items).
Responses were based on the 1-100 mm visual analog scale. Responses were scored using a ruler
to measure the distance in millimeters from the left end to the subjects pencil mark. Scores for
each item were summed to obtain scores for each category: pain and physical function. Higher
scores indicated worse pain and physical function.
For HRV assessment, subjects were instructed to lie still on an examination table in the
laboratory for five minutes. The laboratory was kept quiet and at a comfortable temperature.
Alcohol swabs were used to prep the skin for optimal EKG signal acquisition. Three electrodes
were configured to examine one lead. Wires were color coded white (right arm [RA]), black
(right leg [RL]), and red (left leg [LL]) and were attached at the terminal ends to adhesive
electrodes. Proximal ends of the wires were inserted into the EKG port of the MP1500 system.
The electrodes attached to the RA, RL, and LL wires were placed on the anterior aspect of the
right wrist, and medial aspects of the right and left ankles, respectively. The RA wire represented
the negative aspect, the LL wire represented the positive aspect, and the RL wire was used as the
ground for lead II.
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The experimenter observed the EKG for line noise or unusual rhythms during data
collection. The AcqKnowledge software recorded HRV data through EKG for five minutes. The
subject was instructed to close their eyes and remain still and relaxed during the measurement.
The data collection was terminated and started over if the subject talked or moved during
collection. Once HRV data was collected, data was saved on the computer hard drive and the
electrodes were removed from the subject.
HRV variables were obtained from the raw EKG data using AcqKnowledge software
which used algorithms following the frequency domain guidelines established by the Task Force
of the European Society of Cardiology and The North American Society of Pacing and
Electrophysiology (Task Force) (BIOPAC 2007; Malik et al., 1996). Power frequency for HRV
variables were defined by Task Force guidelines as very low frequency (VLF), ≤ 0.04 Hz, low
frequency (LF), 0.04-0.15 Hz, high frequency (HF), 0.15-0.4 Hz, and very high frequency
(VHF), ≥ 0.4 Hz (Malik et al., 1996). LF to HF ratio (LF/HF ratio) was calculated from the data
using AcqKnowledge software.
The expiratory pause was measured using a SportLine 220 stopwatch. Subjects were
taught to perform the expiratory pause by closing their eyes and inhaling and exhaling as usual.
Following exhalation, subjects were instructed to close their mouth, plug their nose, and hold this
until they felt the very first urge to breathe. At the very first urge to breathe, subjects were
instructed to release from plugging their nose and resume breathing. The expiratory pause was
recorded with the stopwatch from the time the subject plugged their nose to the time at which
they released or inhaled, whichever occurred first. Subjects were allowed to practice the
expiratory pause 1-2 times before the pause was recorded. The expiratory pause was then
recorded three times and the best of these recordings was used for data analysis.
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Data Collection
Data were collected prior to and following the six week DSB program. Data were
collected at the same time period for both the control and experimental groups. WOMAC scores,
HRV, and expiratory pauses were obtained and recorded. Post-test data were collected 48 hours
after the end of the DSB program.

Data Analysis
Analysis was separated into three facets: subjective assessment using WOMAC scores
(pain and physical), objective assessment using HRV variables (LF, HF, and LF to HF ratio), and
evaluation of the training program using the expiratory pause. Means and standard deviations for
pre- and post-intervention were calculated for variables within each facet and compared. Change
scores were calculated for each variable by subtracting the pre-intervention measurement from
the post-intervention measurement. Means and standard deviations were calculated and reported
for the change scores. Pain and physical function were each analyzed using a mixed ANOVA.
LF, HF, and LF/HF ratio were each analyzed using a mixed ANOVA. The expiratory pause was
analyzed using a mixed ANOVA. Change scores were analyzed using a one-way ANOVA.
Caloric intake and energy expenditure were analyzed using two tailed t tests. The alpha level for
analysis was set at less than 0.05. A Bonferroni correction was applied for WOMAC and HRV
facets (p = 0.025 and p = 0.017, respectively). Statistical analysis was used to evaluate if there
was an interaction between group and time or a main effect for group or time. Data analysis was
completed with Excel (Microsoft Inc., Redmond, WA) and IBM SPSS 23 (Armonk, NY).
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Chapter IV
Results and Discussion

Introduction
This study tested the null hypothesis that six weeks of deep slow breathing (DSB)
exercises would not result in significant differences in WOMAC Index scores (pain and physical
function), heart rate variability (LF, HF, and LF/HF ratio), and expiratory pause from pre-test to
post-test between control subjects and subjects that received training. Each subject attended two
data collections approximately six weeks apart. Pain and physical function were assessed with
the WOMAC Visual Analog Scale (VAS) 3.0. Autonomic nervous system activity was assessed
with heart rate variability, specifically low frequency and high frequency components and
sympathetic/vagal ratio. The expiratory pause was measured to determine any differences preand post-test for control and training subjects.

Results
Subject characteristics. Twenty subjects (14 female, 6 male), aged 20-82 (67 ± 9) years
old, participated in this study. Subjects had been diagnosed with osteoarthritis of their hip, knee,
or ankle (n=13) or received a normative score of less than 50 on the American Academy of
Orthopaedic Surgeons (AAOS) Hip and Knee Questionnaire (n=7). Subjects received physician
clearance to participate and had not undergone surgery during the six months prior to the study.
Subject characteristics are presented in Table 1.

37

Table 1. Subject characteristics [mean ± standard deviation (SD)].
Subject Characteristics
Training (n=10)

Control (n=10)

Age (years)

67 ± 9

48 ± 19

Height (m)

1.6 ± 0.1

1.7 ± 0.1

70.5 ± 13.6

73.8 ± 13.4

Weight (kg)

Subjective outcomes: WOMAC VAS pain and physical function. For WOMAC pain
scores, there was not a significant interaction between group and time (F[1, 18] = 1.843, p =
0.191, ηp2 = 0.093) and there was not a significant main effect for group (F[1, 18] = 0.058, p =
0.812, ηp2 = 0.003). There was a significant main effect for time (F[1, 18] = 14.960, p = 0.001)
and the effect size was large (ηp2 = 0.454). For WOMAC physical function scores, there was not
a significant interaction between group and time (F[1, 18] = 0.038, p = 0.848, ηp2 = 0.002) and
there was not a significant main effect for group (F[1, 18] = 0.038 , p = 0.671, ηp2 = 0.010).
There was a significant main effect for time (F[1, 18] = 18.425, p < 0.001) and the effect size
was large (ηp2 = 0.506). Means and standard deviations for pain and physical function are
presented in Table 2 and Figures 1-2.

38

Table 2. WOMAC pain and physical function scores (mean ± SD) for each group pre- and posttest.
Pain
Pre-test

Post-test

Training

148 ± 94

84 ± 89

Control

123 ± 87

92 ± 73

Pre-test

Post-test

Training

434 ± 268

276 ± 287

Control

482 ± 346

338 ± 274

Physical Function

Figure 1. A graphical representation of mean WOMAC VAS pain scores for each group pre- and
post-test.
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Figure 2. A graphical representation of mean WOMAC VAS physical function scores for each
group pre- and post-test.
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The change scores indicated that pain and physical function scores decreased for both
training and control groups, but the changes were not statistically significant. Higher WOMAC
scores indicate worse pain and physical function. The decreases in pain and physical function
scores signify decreases in pain and improvements in physical function. Changes scores were not
statistically significant for pain (F[1, 18] = 1.843, p = 0.191, ηp2 = 0.093) or physical function
(F[1, 18] = 0.038, p = 0.848, ηp2 = 0.002). Means and standard deviations for pain and physical
function change scores are presented in Table 3 and Figures 3-4.
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Table 3. Change in WOMAC pain and physical function scores (mean ± SD) for each group preand post-test.
Change in WOMAC Scores
Pain

Physical Function

Training

-64 ± 69

-158 ± 160

Control

-31 ± 34

-144 ± 155

Figure 3. A graphical representation of change in WOMAC pain scores from pre- to post-test for
each group.
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Figure 4. A graphical representation of change in WOMAC physical function scores from pre- to
post-test for each group.
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Objective outcomes: LF power, HF power, and LF/HF ratio. Analysis was conducted
using data from ten training subjects and nine control subjects because data for one of the control
subjects was not usable. Means and standard deviations for LF power, HF power, and LF/HF
ratio are presented in Table 4 and Figures 5-7. For LF power, there was not a significant
interaction between group and time (F[1, 17] = 0.526, p = 0.478, ηp2 = 0.030). There was not a
significant main effect for group (F[1, 17] = 0.690, p = 0.418, ηp2 = 0.039) and there was not a
significant main effect for time (F[1, 17] = 1.112, p = 0.306, ηp2 = 0.061). Due to the large
standard deviation in pre- and post-intervention measurements, a secondary axis was added to
the graph displaying LF power before and following DSB (Figure 5).
For HF power, there was not a significant interaction between group and time (F[1, 17] =
0.005, p = 0.945, ηp2 = 0.000). There was not a significant main effect for group (F[1, 17] =
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0.687, p = 0.419, ηp2 = 0.039) and there was not a significant main effect for time (F[1, 17] =
0.693, p = 0.417, ηp2 = 0.039) (Figure 6).
For LF/HF ratio, there was not a significant interaction between group and time (F[1, 17]
= 0.627, p = 0.439, ηp2 = 0.036). There was not a significant main effect for group (F[1, 17] =
0.627, p = 0.439, ηp2 = 0.036) and there was not a significant main effect for time (F[1, 17] =
3.464, p = 0.080, ηp2 = 0.169) (Figure 7).

Table 4. Heart rate variability: Low frequency power, high frequency power, and
sympathetic/vagal ratio (mean ± SD) for each group pre- and post-test.
Low Frequency Power (ms2)
Pre-test

Post-test

Training

179.30 ± 562.1

9.82 ± 28.84

Control

32.08 ± 66.55

0.74 ± 0.73

Pre-test

Post-test

14.04 ± 39.76

7.02 ± 19.24

7.43 ± 9.99

1.50 ± 1.87

Pre-test

Post-test

Training

5.64 ± 10.03

2.13 ± 3.72

Control

2.38 ± 3.79

0.97 ± 0.69

High Frequency Power (ms2)

Training
Control
Sympathetic/Vagal Ratio
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Figure 5. A graphical representation of the low frequency (LF) power for each group pre- and
post-test. This figure includes a secondary axis for the post-test LF power because of the large
standard deviation of the post-test data in the training group.
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Figure 6. A graphical representation of high frequency (HF) power for each group pre- and posttest.
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Figure 7. A graphical representation of the sympathetic/vagal ratio for each group pre- and posttest.
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Change scores for HRV indicate that there were no significant differences between the
training and control groups. Change scores were not statistically significant for LF power (F[1,
17] = 0.526, p = 0.478, ηp2 = 0.030), HF power (F[1, 17] = 0.005, p = 0.945, ηp2 = 0.000), or
LF/HF ratio (F[1, 17] = 0.627, p = 0.439, ηp2 = 0.036). Means and standard deviations for HRV
change scores are presented in Table 5 and Figures 8-10.

Table 5. Change in LF power, HF power, and LF/HF ratio scores (mean ± SD) for each group
pre- and post-test.
Change in HRV Scores

Training
Control

LF Power (ms2)

HF Power (ms2)

LF/HF Ratio

-169.57 ± 566.52

-7.02 ± 45.78

-3.51 ± 6.93

-31.34 ± 66.36

5.93 ± 8.95

-1.41 ± 4.07
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Figure 8. A graphical representation of change in LF power from pre- to post-test for each group.
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Figure 9. A graphical representation of change in HF power from pre- to post-test for each group.
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Figure 10. A graphical representation of change in LF/HF ratio from pre- to post-test for each
group.
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Training outcomes: Expiratory pause. Expiratory pause values were similar for
training and control groups. There was not a significant interaction between group and time (F[1,
18] = 0.307, p = 0.586, ηp2 = 0.017). There was not a significant main effect for group (F[1, 18]
= 0.686, p = 0.418, ηp2 = 0.037) and there was not a significant main effect for time (F[1, 18] =
0.111, p = 0.743, ηp2 = 0.006). Means and standard deviations for the expiratory pause are
presented in Table 6 and Figure 11.
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Table 6. Expiratory pause (mean ± SD) for each group pre- and post-test.
Expiratory Pause(s)
Pre-test

Post-test

Training

21 ± 12

23 ± 9

Control

26 ± 10

25 ± 8

Figure 11. A graphical representation of the expiratory pause for each group pre- and post-test.
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Change scores were not statistically significant for the expiratory pause (F[1, 18] = 0.336,
p = 0.569, ηp2 = 0.018). Change scores for the expiratory pause are displayed in Table 7 and
Figure 12.
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Table 7. Change in expiratory pause scores (mean ± SD) for each group pre- and post-test.
Expiratory Pause Change Score (s)
Training

2±12

Control

-1±7

Figure 12. A graphical representation of change in expiratory pause from pre- to post-test for
each group.

Expiratory Pause Change Scores Following Deep Slow
Breathing

Expiratory Pause (s)

15
10
Training
5

Control

0
-5
-10
-15

Subject compliance: Breathing, diet, and exercise logs. Nine of the ten training
subjects completed all weekly breathing logs. The mean amount of time spent practicing DSB at
home each week was 118 minutes with a standard deviation of 22 minutes. For the diet and
exercise logs, eight training subjects and six control subjects completed the logs. The training
group did not show significant changes in diet (p = 0.714) or exercise (p = 0.527) and the control
group did not exhibit significant changes in diet (p = 0.448) or exercise (p = 0.497). Means and
standard deviations for all diet and exercise logs may be found in Table 8.
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Table 8. Diet and exercise (mean ± SD) measures for each group pre- and post-test.
Diet (kcal in)
Pre-test

Post-test

Training

1794.61 ± 833.56

1730.06 ± 863.97

Control

1884.74 ± 711.41

1942.42 ± 612.89

Pre-test

Post-test

48.16 ± 6.60

49.05 ± 4.22

50.96 ± 11. 73

52.48 ± 14.45

Exercise (kcal out)

Training
Control

Discussion
The purpose of this study was to evaluate the effects of a six week DSB exercise program
on pain and physical function in subjects with lower extremity joint pain. The DSB exercise
program was comprised of weekly practice sessions with a trainer and 20-30 minutes of DSB
exercises at home, five days each week. The goal of the DSB exercise program was to lengthen
the exhalation phase of breathing and the pause following exhalation. The null hypothesis stated
that six weeks of DSB would not result in significant changes in WOMAC pain and physical
function scores or HRV variables: LF power, HF power, and LF/HF ratio.
Subjective outcomes: WOMAC VAS pain and physical function. Results from this
study reveal that there was no significant interaction between group and time, and no significant
differences between the training and control groups for WOMAC VAS pain and physical
function scores. However, both training and control groups showed significant changes in pain
and physical function scores from pre- to post-test assessments. Additionally, the mean changes
in pain and physical function met the Minimal Clinically Important Improvement (MCII) criteria
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(Tubach, 2005). However, the standard deviations for pain and physical function scores in both
groups were very large and make it difficult to draw conclusions with regard to MCII criteria.
Results indicate that while there were significant changes in pain and physical function scores,
these changes did not result from the DSB exercise program. Alternatively, the changes in pain
and physical function from pre- to post-test are likely due to another variable affecting both
training and control groups. It is possible that subjects benefited from the social support they
received while participating in the study.
Social support may play an important role in improving pain and physical function for
those suffering with OA (Escobar et al., 2007; Ethgen et al., 2004; Ferreira & Sherman, 2007;
López-Martínez, Esteve-Zarazaga, & Ramírez-Maestre, 2008; Sharma et al., 2003). In studies
evaluating the relationship between social support and OA outcomes, social support protected
subjects against poor WOMAC outcomes (Sharma et al., 2003) and was associated with higher
physical functioning, general health, mental health, social functioning, and vitality (Ethgen et al.,
2004). In addition to social support, optimism may help to mediate pain. Ferreira and Sherman
(2007) investigated the role of social support in well-being and found that social support partially
mediated pain perceptions in relation to depressive symptoms while optimism partially mediated
pain perceptions in relation to life satisfaction. Both social support and optimism seem to be
important mediators of OA pain.
The importance of social support offers an explanation for the significant decrease in pain
and improvement in physical function seen in both groups in the present study. Results of the
present study combined with previous research highlight the potential importance of
psychosocial factors in the adjustment to chronic pain. These results provide support for a
biopsychosocial model of pain. While the DSB exercise program was not sufficient to
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significantly alter WOMAC pain and physical function scores, social support may have played a
role in the improvements seen in both training and control groups. There is currently no research
that evaluates the use of research as a dimension of social support. More research is needed to
confirm the theory that participation in a research study may increase perceived social support
and improve self-reported OA outcomes.
Objective outcomes: LF power, HF power, and LF/HF ratio. Results from this study
reveal that there were no significant interactions between group and time and no main effects for
group or time with respect to LF power, HF power, and LF/HF ratio. These results support the
null hypothesis that a six week DSB exercise program would not significantly alter HRV, an
indicator of autonomic nervous system (ANS) activity. Results of the present study contrast
previous studies which indicate that DSB decreased sympathetic autonomic nervous system (SANS) activity (Busch et al., 2012; Chandla et al., 2013; Pal et al., 2004) and increased
parasympathetic autonomic nervous system (P-ANS) activity (Chalaye et al., 2009; Chandla et
al., 2013; Pal et al., 2004).
Due to the strong relationship between pain and ANS activity (Busch et al., 2012;
Chalaye et al., 2009), it is surprising that the significant changes in WOMAC pain scores in the
present study were not accompanied by significant changes in ANS activity. However, pain was
self-reported and subjective in the present study. Studies supporting the relationship between
pain and ANS activity have objectively measured pain perception by measuring heat pain
threshold and tolerance (Busch et al., 2012; Chalaye et al., 2009). Further research is needed to
examine the relationship between self-reported pain and ANS activity.
Discrepancies between the present study and other research may be due to the
methodology. This study measured HRV within 48 hours of the last at-home breathing exercise
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session. Subjects were allowed to breathe naturally during HRV recording. Most studies
evaluating the effect of breathing on HRV use controlled breathing during HRV recording or
measure HRV immediately after the DSB session (Busch et al., 2012; Chalaye et al., 2009).
Chandla et al. (2013) studied the effects of a six week DSB program, using pranayama, and
found significant increases in HF power and decreases in LF power and LF/HF ratio. However,
they did not report the procedures used during HRV recording. It is unknown if subjects breathed
naturally or used controlled breathing during HRV recording for this study.
Breathing patterns during HRV recording may significantly impact HRV results. In a
study of 24 healthy males, the effect of different breathing patterns on HRV was assessed. HRV
and respiratory rate were recorded during several conditions: voluntary breathing at rest and
metronome guided breathing at 0.1, 0.2, and 0.4 Hz during rest and cycling. Results indicated
that the breathing pattern had a moderate effect on LF power (η2 = 0.125) and LF/HF ratio (η2 =
0.082) and a strong effect on HF power (η2 = 0.204) (Weippert, Behrens, Rieger, Kumar, &
Behrens, 2015). These results are supported by a study which suggests that changes in HRV at
respiratory frequencies (0.15-0.5 Hz) may be due to respiration. This study also examined the
effect of respiratory frequency on changes in LF power (Beda, Simpson, Carvalho, & Carvalho,
2014). Beda et al. demonstrated that up to 79 percent of changes in the LF power could be
predicted by respiratory parameters such as respiratory period, tidal volume, and the tidal volume
power in the LF band (VLF,n). These results reveal the relationship between respiratory variability
and HRV and suggest that it is important to measure and assess respiration with HRV.
Along with respiratory rate, respiratory ratio may play a key role in altering HRV. In a
study by Van Diest et al. (2014), subjects were instructed to breathe at 6 or 12 breaths per minute
with an inhalation/exhalation (i/e) ratio of 0.42 or 2.33. The lower i/e ratio was associated with
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an increase in HF power, but only for the slow breathing pattern (F[1,22] = 36.12, p < 0.025).
Results of this study indicate that both the respiratory rate and i/e ratio are important modulators
of HRV (Van Diest et al., 2014). Both of these variables should be measured and considered
when interpreting HRV data. With breathing patterns such as high frequency yoga breathing and
breathing awareness, that breathing-related changes in HRV may last for up to 15 minutes
following the return to uncontrolled or natural breathing (Telles, Singh, & Balkrishna, 2011).
Therefore, it may also be important to consider the breathing pattern of an individual before
HRV data collection begins.
The methods of Kulur, Haleagrahara, Adhikary, and Jeganathan (2009) may be an
effective way of measuring the effects of a DSB program on HRV. Kulur et al. trained subjects
to breathe at a rate of six respiratory cycles per minute, five seconds for inhalation and five
seconds for exhalation, during HRV recording. During the intervention, subjects were trained
with diaphragmatic breathing and follow-up recording was completed at three months and one
year. This methodology would help control for the changes in autonomic activity caused by
respiratory variability during HRV recording.
Due to the influence of respiration on HRV (Beda et al., 2014; Shirley Telles et al., 2011;
Van Diest et al., 2014), controlling for respiratory variability during pre- and post-intervention
HRV data collection may provide a more accurate assessment of the effects of a breathing
intervention on HRV. Previous research on the relationship of respiratory variability and HRV
may partially explain the lack of significant changes in HRV in the present study. Furthermore,
the large standard deviations seen in the training group may be the result of greater respiratory
variability due to increased breathing awareness (Telles et al., 2011). More research is needed to
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examine the effects of DSB programs on HRV, utilizing controlled breathing during HRV data
collection.
Training outcome: Expiratory pause and anecdotal outcomes. There was not a
significant interaction between group and time and there were also no significant main effects for
group or time for the expiratory pause. Results reveal that the DSB exercise did not effectively
increase the expiratory pause. While there is anecdotal evidence that the expiratory pause may be
increased through training (Chaitow et al., 2014), there is no scientific evidence supporting this
claim. This may explain why there were no significant changes in the expiratory pause during the
course of the study. More research is needed to determine if the expiratory pause can be
increased and the amount of training and time needed to induce chances in the expiratory pause.
In addition to measured outcomes of this study, anecdotal results were also recorded.
While no control subjects reported perceived changes during the study, eight training subjects
reported a decrease in their stress level and an increase in their perceived ability to effectively
manage stress. Eight subjects reported that the breathing exercises helped them to cope with their
joint pain, even when the pain did not subside following the DSB exercises. Eight training
subjects reported increased awareness of both their breathing patterns and awareness of tension
in their bodies. All training subjects reported being able to effectively release tension in their
body and relax using the breathing exercises. Additionally, six subjects reported improved
physical function, five subjects reported improved mood, three subjects reported decreased pain,
and two subjects reported improved sleep quantity and quality.
Limitations. Additional limitations of this study involve the lack of control for other
variables such as age, body mass index, knee pain intensity, disease severity, and additional
potential confounders. The small, non-random nature of the sample may have also affected the
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results and limited the generalizability of the results. Additionally, the large standard deviations
of all variables and the self-report nature of the WOMAC assessment of pain and physical
function may have affected the results.

Summary
Six weeks of DSB did not significantly alter pain-related variables in subjects with lower
extremity joint pain. However, both training and control groups experienced significant
decreases in pain and significant improvements in physical function over the course of the study.
Changes in pain and physical function from pre- to post-test appear to be the result of social
support that subjects received by participating in the study. The lack of significant changes in
HRV variables may have been due to the large standard deviations and the lack of breathing
control during HRV data collection. Further research is needed as the present study is the first to
evaluate the use of DSB as an intervention for arthritis-related pain and physical limitation.
Additional research would also ideally identify subjects with arthritis who would benefit most
from DSB and the amount of DSB needed to produce significant or minimal clinically important
improvements in pain and physical function.
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Chapter V
Summary, Conclusions, and Recommendations

Summary
Effective and novel interventions for arthritis-related symptoms are important as arthritis
is the leading cause of disability among adults in the United States and current non-surgical
interventions have low efficacy (CDC, 2013; Losina et al., 2014). Breathing exercises have been
used for years in a clinical setting to reduce pain and improve health, especially in labor and
delivery (Lothian, 2011). However, they have not been used as an intervention for OA. Recent
studies suggest that deep slow breathing (DSB) relieves pain (Chalaye et al., 2009) and improves
mood (Busch et al., 2012). DSB reduces pain in healthy subjects by increasing pain threshold,
increasing parasympathetic activity (Chalaye et al., 2009), decreasing sympathetic activity
(Busch et al., 2012), and altering pCO2 and pH (Chaitow et al., 2014). Breathing also improves
mood, which would improve depressive symptoms associated with arthritis (Busch et al., 2012).
As the prevalence of arthritis rises (CDC, 2013), cost-effective interventions that target
pain are highly valuable. The role of DSB in improving joint pain has not previously been
studied. DSB may be an effective method for improving pain, function, and mood. This model
may be especially appealing to patients with arthritis because the time commitment and cost are
less than traditional therapeutic measures, DSB puts no mechanical stress on the joints, and DSB
may be relaxing for those with OA. As symptoms improve with the use of DSB, those with
arthritis may be more likely to participate in other physical activities, resulting in further health
benefits. The purpose of this study was to determine if a significant difference existed in joint
pain perception and heart rate variability (HRV) following a six week DSB exercise program. A
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better understanding of the effects and mechanisms of DSB may provide novel and practical
approaches to treating joint pain.

Conclusions
The results of this study indicate that six weeks of DSB did not produce significant
changes in pain, physical function, LF power, HF power, or LF/HF ratio. However, both training
and control groups exhibited significant changes in WOMAC pain and physical function scores
from pre- to post-intervention. These changes may have been due to an increased perception of
social support during participation in the study. The lack of significant differences in HRV
parameters may be due to the lack of breathing control during HRV data collection. The absence
of breathing control may have also resulted in the large standard deviations seen in the HRV
data. This is the first study to examine the efficacy of DSB as an intervention for joint pain and
physical limitation. Furthermore, research on DSB as an intervention for chronic pain is limited.
Further research is needed to evaluate the use of breathing exercises as an intervention for joint
pain.

Recommendations
Future research. The current study is the first to investigate the efficacy of DSB as an
intervention for lower extremity joint pain and functional limitations. Further research is needed
to investigate the efficacy of DSB and to determine the type and dosage of DSB needed to
produce significant changes in pain and physical function. Part of the difficulty in studying pain
is the measurement. Pain is usually assessed by pain scales, questionnaires, or measurements of
pain threshold (Busch et al., 2012; Chalaye et al., 2009; Chambers et al., 2009). However, there
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is some research that suggests that certain areas of the brain become active when a person
experiences pain. This network is known as the “pain matrix” (Kulkarni et al., 2007). Future
studies should utilize functional magnetic resonance imaging (fMRI) to assess the changes in
activity of the pain matrix during DSB exercises. In order to effectively study the pain matrix,
however, subjects would need to be in pain when the imaging began and complete the DSB
exercises while experiencing pain. This type of study would assist researchers in determining the
amount of DSB that is needed to decrease pain.
Due to the relationship between respiratory variability and HRV, future studies utilizing
HRV to evaluate autonomic nervous system (ANS) activity should measure, assess, and consider
respiratory variability during HRV data collection. Additionally, research is needed to determine
if the effects of DSB on HRV are acute or produce lasting changes. If the changes in HRV
persist, research is needed to determine the length of time that changes in HRV persist.
Respiratory parameters such as respiratory rate and depth, forced expiratory volume in one
second (FEV1.0), minute ventilation (MVV), and diaphragmatic excursion would also provide
more information about possible mechanisms of action and help determine how DSB alters
respiratory physiology.
Results of this study may also underscore the role of social support in mediating pain and
physical limitations. To date, studies have examined social support using questionnaires, selfreported measurements, or marital and living status (Ethgen et al., 2003; Escobar et al., 2006;
Sharma et al., 2003). There are no studies evaluating the use of club activities, support groups, or
participation in research as an intervention for arthritis. Future studies should investigate the role
of different forms of social support in deceasing pain and improving physical function in those
with arthritis.
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This study may be used to develop future studies that further probe the use of DSB as an
intervention for joint pain and dysfunction. Further research will provide more information about
the role of DSB as an intervention for joint pain. A better understanding of the effects and
mechanisms of DSB may provide novel and practical approaches to treating joint pain.
Practical applications. At this time, DSB does not appear to produce significant changes
in OA joint pain or physical function. Anecdotal evidence from this study, however, indicates
that DSB may help those with arthritis to cope with pain by reducing stress and increasing
awareness of tension and breathing patterns. Although the purpose of this study was not to
examine the effect of social support on pain-related symptoms, this study highlights the potential
role of support as a mediator of pain and functional limitations and provides support for a
biopsychosocial model of pain. Club activities or support groups may be beneficial for those
experiencing joint pain and dysfunction.
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Human Subjects Activity Review
1. What is your research question, or the specific hypothesis?
This study examines the effects of a six week deep slow breathing program on
Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index scores,
heart rate variability (HRV), and expiratory pause in subjects with osteoarthritis (OA) of
the hip and knee.

2. What are the potential benefits of the proposed research to the field?
The proposed research will investigate the efficacy of a breathing program for
those suffering with arthritis. Arthritis is the leading cause of disability among adults in
the United States, affecting an estimated 50 percent of people age 65 and older. The
disease costs the United States approximately 128 billion dollars in medical care and lost
wages annually and is associated with other health disorders such as diabetes,
hypertension, obesity, and cancer. Furthermore, half of those with arthritis also suffer
from cardiovascular disease, the leading cause of death among both men and women in
the United States (Centers for Disease Control and Prevention (CDC), 2013).
OA is the most common form of arthritis, mainly affecting the hands, hips, and
knees. Those suffering from OA experience a great deal of pain, limiting physical activity
and decreasing quality of life. Fear of pain or worsening symptoms may discourage those
with OA from beneficial exercise, leading to other health problems associated with OA
(CDC, 2013). Because pain is the major limiting factor for those with OA, most
interventions are aimed at reducing pain. However, surgical intervention is expensive and
non-surgical interventions have low efficacy (Losina et al., 2014). Some interventions,
such as pain relievers, may produce other health complications, such as damage to the
liver, kidneys, and gastrointestinal (GI) tract (Max & Stewart, 2008; Michael et al.,
2010).
There is a need for effective non-surgical interventions. Exercise has been
proposed as an effective and beneficial intervention for those with arthritis. Exercise
reduces pain and improves function, quality of life, mood, and confidence to manage
health (CDC, 2013). Despite the benefits of exercise, 60 percent of people suffering with
the disease do not adhere to physical activity guidelines and 23 percent are categorized as
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physically inactive. This decrease in physical activity (hypokinesis) in those with OA
may be a result of pain or fear of worsening symptoms with exercise (Austin et al., 2012).
Hypokinesis progresses OA by increasing stiffness and weakness in the joints and
causing metabolic acidosis and chronic inflammation, making exercise even more
challenging (Michael et al., 2010).
Since aerobic and resistance training are effective non-surgical interventions but
many with OA will not participate, alternative exercises must be evaluated. Breathing
exercises have been used for years in a clinical setting to reduce pain and improve health,
especially in labor and delivery (Lothian, 2011). However, they have not been applied as
an intervention for OA. Respiration plays an important role in pain signaling and
autonomic system activation, emotion regulation, acid/base balance, and antiinflammatory processes. Recent studies suggest the deep slow breathing relieves pain
(Chalaye et al., 2009) and improves mood (Busch et al., 2012). Studies in healthy
subjects reveal that deep slow breathing (DSB) reduces pain by increasing pain threshold,
increasing parasympathetic activity (Chalaye et al., 2009), decreasing sympathetic
activity (Busch et al., 2012), and altering pCO2 and pH (Chaitow et al., 2014). Breathing
also improves mood, which would greatly impact those with OA since many suffer from
depression as well (Busch et al., 2012).
DSB has not been studied as an intervention for OA, but may be an effective
method for improving pain, function, and mood. This exercise model may be appealing to
patients with OA because the time commitment and cost are less than traditional
therapeutic measures. In addition, DSB puts no mechanical stress on the joints and may
be relaxing for those with OA. As symptoms improve with the use of DSB, those with
OA may be more likely to participate in other physical activities, resulting in further
health benefits. Results from this study will provide information about the role of DSB in
relieving OA pain. A better understanding of the effects and mechanisms of DSB may
provide novel and practical approaches to addressing OA limitations.
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3. What are the potential benefits, if any, of the proposed research to the subjects?
This research may provide support for the use of deep slow breathing for pain
alleviation. Subjects will receive deep slow breathing training and may use the techniques
after the study if they are effective.

4. A. Describe how you will identify the subject population, and how you will contact
key individuals who will allow you access to that subject population or database.
Participants with OA, defined by the Centers for Disease Control and Prevention
(2013), will be recruited from the Arthritis Foundation, Bellingham Senior Activity
Center, and Blaine Senior Activity Center. The primary researcher currently volunteers at
the Arthritis Foundation and will teach a class on dealing with OA pain. At the end of the
class, the primary researcher will recruit subjects for this study. The primary researcher
will also recruit subjects at Arthritis Foundation events as well as distribute posters. The
researcher will also recruit subjects at the Senior Activity Centers in Bellingham and
Blaine, WA. Managers from the Arthritis Foundation and Senior Activity Centers have
given their consent for the primary researcher to recruit subjects through them. The
consent forms are attached to this document.

B. Describe how you will recruit a sample from your subject population, including
possible use of compensation, and the number of subjects to be recruited.
At least 30 subjects will be recruited for this study. Subjects must have physiciandiagnosed moderate to severe, unilateral or bilateral OA of the hip and/or knee joint(s).
Subjects with unilateral OA must not have a history of joint replacement surgery.
Subjects with bilateral OA who have undergone joint replacement surgery on only one
joint will be allowed to participate. The joint that has not been operated on will be used
for assessment with WOMAC. For subjects with bilateral OA that have not undergone
joint replacement surgery, the extremity with more severe pain, determined by the
WOMAC pain score, will be used for WOMAC assessment. No subjects will have
undergone joint surgery within the last six months. All subjects will obtain medical
clearance from a physician to participate in the study.
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5. Briefly describe the research methodology. Attach copies of all test
instruments/questionnaires that will be used.
Design of the study: This study will utilize a pretest-posttest randomized groups
experimental design in which subjects will be randomly assigned to either the control or
training group. Subjects will be randomly assigned to either the control or training group
by drawing a piece of paper from a paper bag. Those who drew a paper with a “C” were
assigned to the control group and those who drew a paper with a “T” were assigned to the
training group.

Instrumentation: Heart rate variability (HRV) will be measured using Biopac (Goleta,
CA). Disposable adhesive electrodes will be used for the subject-EKG interface and HRV
measurements will be taken with a standard 3-electrode, 1-lead EKG setup which
examines lead II. An MP100 (BIOPAC Systems Inc., Goleta, CA) interfaced with a
Pentium III computer will be used. AcqKnowledge software (BIOPAC Systems Inc.,
Goleta, CA) was used for data recording, collection, and data reduction. The Visual
Analog Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index will
be used to assess pain and physical function. Nutritionist Pro software (Redmond, WA)
will be used to measure caloric intake and the Bouchard method will be used to
determine energy expenditure (Bouchard et al., 1983) before and after the study.

Experimental protocol: The study will be conducted over six weeks. All subjects will be
instructed not to alter diet or physical activity. Three day diet and physical activity logs
will be completed pre and post breathing intervention to verify that no substantial
changes were made in diet or physical activity. Subjects will be instructed to notify the
researcher if they begin a new medication. Subjects who begin new medications will be
excluded from the study. The control group will not attend weekly breathing training.
The training group will attend weekly breathing training.
Breathing training will take place at Western Washington University, Bellingham
Senior Activity Center, and Blaine Senior Activity Center. Subjects will be instructed to
wear comfortable and loose fitting clothes. Weekly sessions will last for 30 minutes.
Subjects will be divided into groups of 3-4 subjects. During breathing training, all
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subjects will sit upright on a chair with back support. Subjects will be informed of the
discomfort or “air hunger” they may experience during breathing exercises. Subjects will
be assured that they may take a break if they feel dizzy or out of breath.
During the first ten minutes of breathing training, subjects will be instructed to
place one hand on their abdomen and one hand on their chest and focus on breathing at a
slow and comfortable pace. Subjects will be instructed to inhale through their nose and
exhale through their mouth. Once subjects are comfortable and focused on their
breathing, ten minutes will be spent practicing the expiratory pause. Subjects will
perform the expiratory pause following normal inhalation and exhalation. Following
exhalation, subjects will plug their nose with their fingers and close their mouth. This will
be held until the subject feels the urge to inhale. The amount of time that a subject can
hold this pause will be recorded as the expiratory pause (Chaitow et al., 2014).
Specific values for depth and frequency of breathing will not be used in this
study. The expiratory pause will aid subjects in reducing breath frequency. The remaining
ten minutes of training will be used to record breath frequency by counting the number of
breaths per minute. Breathing frequency will be use to verify that the breathing training is
decreasing breath frequency.
Training subjects will also be instructed to complete the breathing exercise with
the expiratory pause at home five days a week for 20-30 minutes each day (Chaitow et
al., 2014). Subjects will keep a log of breathing exercises. Subjects will be given written
instructions and a link to an instructional YouTube video produced by the researcher to
help them practice during the week. On the day of the weekly group training session,
subjects will not be required to complete additional breathing exercises at home.
If subjects miss a weekly training session with the researcher, they will be
required to make up the session on another day with the trainer. If subjects miss an athome session, they will be instructed to continue as usual the next day, without making
up the missed session. If they miss more than three at home sessions, they will be
excluded from the study. Training group subjects will be instructed not to complete
breathing exercises on the day of data collection.
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Measurement techniques and procedures: Subjects will self-report their age and sex.
Body height will be measured by the researcher using a stadiometer. Body weight will be
measured using a medical scale.
For HRV measurements, subjects will be instructed to lie on an examination table
in the laboratory. Alcohol swabs will be used to prepare the skin for optimal EKG signal
acquisition. Three electrodes will be configured to examine one lead. Wires will be color
coded (right arm [RA]), black (right leg [RL]), and red (left leg [LL]) and equipped with
clips at the terminal ends for placement of adhesive electrodes. Proximal ends of the
wires will be inserted into the EKG port of the MP100 system. The electrodes attached to
the RA, RL, and LL wires will be placed on the anterior aspect of the left wrist, and
medial aspects of the right and left ankles, respectively. The RL wire will be used as the
ground, the RA wire will represent the negative aspect, and the LL wire will represent the
positive aspect of lead II. The experimenter will observe for line noise or unusual
rhythms during data collection. The AcqKnowledge software will record HRV data
through EKG for five minutes. The subjects will be instructed to remain still and relaxed
during the measurement. Once HRV data is collected, data will be saved and the
electrodes will be removed from the subject. HRV variables will be obtained from the
raw EKG data using AcqKnowledge software (BIOPAC, Goleta, CA).
Subjects will perform three timed trials of the expiratory pause. The longest time
for these trials will be used for data analysis. The WOMAC will be used to measure pain
(five items) and physical function (17 items). Responses will be based on the 1-100 mm
visual analog scale. Responses will be scored using a ruler to measure the distance in
millimeters from the left end to the subjects pencil mark. Scores for each item will be
averaged to obtain average scores for each category: pain and physical function. Higher
scores indicate worse pain and physical function.

Data collection: Data will be collected prior to and following the six weeks of training or
no training (control group). Data will be collected at the same time for both the control
and training groups. HRV, WOMAC Index scores, and expiratory pause values will be
obtained and recorded.
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Data analysis: Analysis will be separated into three facets: HRV, WOMAC Index
scores, and expiratory pause. Diet (caloric intake) and exercise (energy expenditure) will
be analyzed, additionally, to verify that no substantial changes were made to diet or
exercise levels. Means and standard deviations pre and post intervention will be
calculated for variables within each facet and compared pre and post. Each HRV variable
(LF and LF/HF) will be analyzed using a two way ANOVA. WOMAC Index variables
(pain and physical function) will each be analyzed using a two way ANOVA. Expiratory
pause will also be analyzed using a two way ANOVA. Caloric intake and energy
expenditure will be analyzed using two tailed t-tests. The alpha level for all analyses will
be set at less than 0.05 with a Bonferroni correction applied for HRV variables and also
separately for the WOMAC domains. Results will be compared between control and
training groups. Data analysis will be completed with Excel (Microsoft Inc., Redmond,
WA) and SPSS (Armonk, NY).

6. Give specific examples (with literature citations) for the use of your test
instruments/questionnaires, or similar ones, in previous similar studies in your field.
No previous research has examined the effects of deep slow breathing on OA
pain. Research examining the effects of deep slow breathing on pain in healthy
individuals and those with cardiovascular disease revealed that deep slow breathing
alleviated pain (Busch et al., 2012; Chalaye et al., 2009; Chandla et al., 2013). In order to
examine the effect of deep slow breathing on OA pain, the WOMAC is a good indicator.
The WOMAC is one of the most commonly used self-reported measures of lower
extremity symptoms and function. It was specifically designed to evaluate pain, function,
and stiffness in subjects with osteoarthritis of the hip and knee. The WOMAC has been
studied for over 30 years in various contexts and in subjects of different ethnic
backgrounds (McConnell et al., 2001). The WOMAC is supported as a valid and reliable
measurement of pain and function in subjects with hip or knee osteoarthritis (Bellamy et
al., 1988; Pua et al., 2009; Wolfe & Kong, 1999).
DSB is hypothesized to improve pain in healthy individuals by increasing
parasympathetic activity (Chalaye et al., 2009) and decreasing sympathetic activity
(Busch et al., 2012). Many studies have found an increase in parasympathetic activity
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(vagal tone) with deep slow breathing exercises (Chalaye et al., 2009; Chandla et al.,
2013; Pal et al., 2004). Since vagal tone cannot be directly measured, HRV is used to
denote vagal activity (Chalaye et al., 2009). DSB-related changes in autonomic activity
have not been measured in subjects with OA.
Likewise, the expiratory pause has not been measured in subjects with OA.
However, the expiratory pause has been studied in subjects with asthma. The control
pause improves asthmatic symptoms, but does not change pulmonary function (Cooper et
al., 2003). This study will provide more information about the role of DSB and the
expiratory pause in alleviating pain and altering autonomic activity.

7. Describe how your study design is appropriate to examine your question or specific
hypothesis. Include a description of controls used, if any.
This study is a pretest-posttest randomized groups experimental design in which
subjects will be randomly assigned to either the control or training group. At least thirty
volunteers will participate in the study. Deep slow breathing training will be compared
pre and post. Results will be compared between the control and training groups. The
control group will be used to verify that results in the training group are actually due to
the breathing training. Diet and exercise journals will be used to verify that results are not
due to substantial changes in diet or exercise. This study design is appropriate to examine
the effect of a six week deep slow breathing program on HRV, WOMAC Index scores,
and expiratory pause in subjects with OA of the hip and knee. Specifically, this design
allows the researcher to compare differences in variables pre and post as well as between
control and training groups.

8. Give specific examples (with literature citation) for the use of your study design, or
similar ones, in previous similar studies in your field.
Many studies have used the pretest-posttest randomized groups experimental design to
investigate the effects of deep slow breathing on pain-related variables such as pain
threshold and pain tolerance (Busch et al., 2012; Chalaye et al., 2009). Surprisingly, very
few studies have used a control group while studying the effects of deep slow breathing.
Chandla et al. (2013) used a control group with the pretest-posttest randomized groups
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experimental design and found a significant difference between the deep slow breathing
(pranayama) group and the control group. Without a control group, it is difficult to
conclude that results are due to breathing exercises rather than education or some other
factor during the experiment.

9. Describe the potential risks to the human subjects involved.
As with any breath holding exercise, potential risks include feelings of breathlessness,
“air hunger,” dizziness, and light headedness, and/or fainting. Discomfort during
breathing exercises is expected, especially during the first training session.

10. If the research involves potential risks, describe the safeguards that will be used to
minimize such risks.
Subjects will be informed of the discomfort or “air hunger” they may feel during the
exercises. They will be instructed to notify the instructor if they feel any discomfort and
they will be encouraged to take a break from the activity until they feel comfortable to
participate again. The researcher will emphasize that the subjects are to hold their breath
until the first urge to breathe and no longer than this urge. The subjects will perform all
breathing exercises in a seated position in a chair with back support with their feet flat on
the floor. This will help protect subjects from injury in the unlikely event that a subject
passes out. The researcher and research assistants will carefully observe subjects to
ensure that breathing exercises are being performed correctly and subjects are not holding
their breath longer than they should.

11. Describe how you will address privacy and/or confidentiality.
All data collected will be kept completely confidential. The data will be stored on a
password protected computer and stored separately from the signed consent forms. Data
will be analyzed by subject number and only primary researchers will have access to the
records.
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The Effect of Deep Slow Breathing on Pain-Related Variables
Physical Education, Health, and Recreation Department
Western Washington University
Informed Consent
You are invited to participate in a research study conducted by Kalee Larsen, from the
Department of Physical Education, Health, and Recreation at Western Washington University.
This study involves research on the effects of deep slow breathing on pain-related variables.
Deep slow breathing is often used to alleviate pain and improve physical function and mood. The
effects of deep slow breathing on lower extremity joint pain have not been studied. The purpose
of this research is to investigate the effects of a six week deep slow breathing program on lower
extremity joint pain and function.
Given your consent, you will be assigned to either the control group or the training group.
Everyone will attend two testing sessions at Western Washington University: during week one
and week eight of the study. If you are assigned to the control group, you will be asked not to
alter your diet or physical activity level for the six week period between data collections. If you
are assigned to the training group, you will be asked not to alter your diet or physical activity
level and you will attend six weeks of deep slow breathing training at Bellingham Senior
Activity Center or Blaine Senior Center.
Testing sessions: Both sessions will involve the same procedures for control and training
group subjects. You will be asked to complete the Western Ontario and McMaster Universities
Osteoarthritis (WOMAC) Index, a questionnaire designed to evaluate joint pain and physical
function. You will be asked to lie on an examination table for five minutes while heart rate
variability (HRV) measurements are taken. For this measurement, electrodes will be placed on
the skin of your right arm, right leg, and left leg and you will be required to be completely still
while data is collected. This is the same procedure as a standard electrocardiogram (EKG), but a
longer recording of six minutes is taken. You will be asked to complete an expiratory pause,
performed by breathing in and breathing out then holding your breath until you feel the first urge
to breathe. The researcher will measure how long you can hold this pause before you feel the
first urge to breathe. The expiratory pause will be taken three times and the best time will be
used for data analysis. In addition to these measurements, you will be asked to complete a three
day diet and exercise log before each data collection. The researcher will provide you with the
log to fill out and bring with you to each data collection.
Breathing training sessions: If you are assigned to the training group, you will complete a
six week deep slow breathing training program. You will attend weekly training sessions with
the researcher at the Bellingham Senior Activity Center or Blaine Senior Center. You will also
complete 20-30 minutes of deep slow breathing at home five days a week.
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As with any breathing exercise, potential risks include feelings of breathlessness, “air
hunger,” dizziness, light headedness, and/or fainting. If you experience any of these feelings, you
should alert the researcher immediately. Discomfort during breathing exercises is expected,
especially during the first training session. Supervision of breathing exercise is done to minimize
the risk of injury or adverse effects. You may take a break from the exercise if you experience
discomfort and you may withdraw from participation in this study at any time, without penalty.
This study is potentially beneficial because it will provide information about the effects
of deep slow breathing on joint pain. At the conclusion of the study, control subjects will be
given the opportunity to be trained with the breathing techniques.
Questions regarding this study and the procedures will be answered by the primary
researcher, Kalee Larsen, who may be contacted at Kalee.Larsen@wwu.edu or 360-319-4350 or
Dr. Lorrie Brilla, who may be contacted at Lorrie.Brilla@wwu.edu or 360-650-3056.
Questions about your rights as a research subject should be directed to Janai Symons, the
WWU Research Compliance Officer (RCO), at Janai.Symons@wwu.edu or 360-650-3082. If
you experience injury or any adverse effect from this study, contact Kalee Larsen, Dr. Lorrie
Brilla, or Janai Symons.
All data collected will be kept completely confidential. The data will be stored on a
password protected computer and external hard drive and stored separately from the signed
consent forms. Data will be analyzed by subject number and only primary researchers will have
access to the records.
Your signature indicates that you have read and understand the information provided
above, that you willingly agree to participate, that you may withdraw your consent at any time
and discontinue participation without penalty, that you have received a copy of this form, and
that you are not waiving any legal claims, rights, or remedies. Thank you for your participation
in this study.

__________________________________________________

_____/_____/_____

Participant’s Full Name (Printed)

Date

__________________________________________________
Participant’s Signature
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PERMISSION FORM TO CONTACT SENIORS FOR TESTING

Letter of permission:
As the manager of the Arthritis Foundation, I, ___________________________, consent to
allow Kalee Larsen to recruit subjects from the Arthritis Foundation for thesis research, which
includes physiological measurements before and following a six week breathing intervention.

__________________________________
Director’s Name (Please Print)

_____/_____/_____
Date

__________________________________
Director’s Signature
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PERMISSION FORM TO CONTACT SENIORS FOR TESTING

Letter of permission:
As the manager of the Bellingham Senior Activity Center, I, ___________________________,
consent to allow Kalee Larsen to recruit members of the Bellingham Senior Activity Center for
thesis research, which includes physiological measurements before and following a six week
breathing intervention.

__________________________________
Director’s Name (Please Print)

_____/_____/_____
Date

__________________________________
Director’s Signature
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PERMISSION FORM TO CONTACT SENIORS FOR TESTING

Letter of permission:
As the manager of the Blaine Senior Activity Center, I, ___________________________,
consent to allow Kalee Larsen to recruit members of the Blaine Senior Activity Center for thesis
research, which includes physiological measurements before and following a six week breathing
intervention.

__________________________________
Director’s Name (Please Print)

_____/_____/_____
Date

__________________________________
Director’s Signature
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Research Pre-Participation Packet

Dear Participant,
Thank you for volunteering for this study. This research will provide important
information about how deep slow breathing exercises affect joint pain and physical function.
Before we begin, the following forms must be completed and returned to Kalee Larsen, the
primary researcher.


Study description



Informed consent



Physician clearance form



Health history form
Please provide your physician with the study description, informed consent, and

physician clearance form. Your physician will need to read the study description and informed
consent before signing the physician clearance form. Please also read and sign the informed
consent and fill out the health history form. This will help us to provide the safest conditions for
you during the study. If you have any questions, contact Kalee Larsen at (360) 319-4350 or
Kalee.Larsen@wwu.edu.
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Study Description
This study examines the effects of a six week deep slow breathing program on pain and
physical function in subjects with lower extremity joint pain. Subjects will be randomly assigned
to either the control or training group. All subjects will attend two data collections at Western
Washington University: one before and one after the six week period. Training subjects will also
complete six weeks of deep slow breathing training. Training subjects will attend a weekly
breathing training session at the Bellingham Senior Activity Center or Blaine Senior Center.
Training subjects will also complete at-home breathing exercises for 20-30 minutes, five days a
week. Breathing exercises will be performed while subjects are seated in a chair with back
support with their feet flat on the floor. Breathing training will focus on prolonging the
expiration and performing an expiratory pause. The expiratory pause is performed following
normal inhalation and exhalation. Following exhalation, the subject will plug their nose and
close their mouth. This will be held until the first urge to breathe. The amount of time a subject
can hold this is defined as the expiratory pause. Pain and physical function will be measured
before and after the study using the Western Ontario and McMaster Universities Osteoarthritis
Index. Autonomic nervous system activity will be assessed with heart rate variability. The
expiratory pause will also be performed and measured before and after the study.
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The Effect of Deep Slow Breathing on Pain-Related Variables
Physical Education, Health, and Recreation Department
Western Washington University
Informed Consent
You are invited to participate in a research study conducted by Kalee Larsen, from the
Department of Physical Education, Health, and Recreation at Western Washington University.
This study involves research on the effects of deep slow breathing on pain-related variables.
Deep slow breathing is often used to alleviate pain and improve physical function and mood. The
effects of deep slow breathing on lower extremity joint pain have not been studied. The purpose
of this research is to investigate the effects of a six week deep slow breathing program on lower
extremity joint pain and function.
Given your consent, you will be assigned to either the control group or the training group.
Everyone will attend two testing sessions at Western Washington University: during week one
and week eight of the study. If you are assigned to the control group, you will be asked not to
alter your diet or physical activity level for the six week period between data collections. If you
are assigned to the training group, you will be asked not to alter your diet or physical activity
level and you will attend six weeks of deep slow breathing training at Bellingham Senior
Activity Center or Blaine Senior Center.
Testing sessions: Both sessions will involve the same procedures for control and training
group subjects. You will be asked to complete the Western Ontario and McMaster Universities
Osteoarthritis (WOMAC) Index, a questionnaire designed to evaluate joint pain and physical
function. You will be asked to lie on an examination table for five minutes while heart rate
variability (HRV) measurements are taken. For this measurement, electrodes will be placed on
the skin of your right arm, right leg, and left leg and you will be required to be completely still
while data is collected. This is the same procedure as a standard electrocardiogram (EKG), but a
longer recording of six minutes is taken. You will be asked to complete an expiratory pause,
performed by breathing in and breathing out then holding your breath until you feel the first urge
to breathe. The researcher will measure how long you can hold this pause before you feel the
first urge to breathe. The expiratory pause will be taken three times and the best time will be
used for data analysis. In addition to these measurements, you will be asked to complete a three
day diet and exercise log before each data collection. The researcher will provide you with the
log to fill out and bring with you to each data collection.
Breathing training sessions: If you are assigned to the training group, you will complete a
six week deep slow breathing training program. You will attend weekly training sessions with
the researcher at the Bellingham Senior Activity Center or Blaine Senior Center. You will also
complete 20-30 minutes of deep slow breathing at home five days a week.
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As with any breathing exercise, potential risks include feelings of breathlessness, “air
hunger,” dizziness, light headedness, and/or fainting. If you experience any of these feelings, you
should alert the researcher immediately. Discomfort during breathing exercises is expected,
especially during the first training session. Supervision of breathing exercise is done to minimize
the risk of injury or adverse effects. You may take a break from the exercise if you experience
discomfort and you may withdraw from participation in this study at any time, without penalty.
This study is potentially beneficial because it will provide information about the effects
of deep slow breathing on joint pain. At the conclusion of the study, control subjects will be
given the opportunity to be trained with the breathing techniques.
Questions regarding this study and the procedures will be answered by the primary
researcher, Kalee Larsen, who may be contacted at Kalee.Larsen@wwu.edu or 360-319-4350 or
Dr. Lorrie Brilla, who may be contacted at Lorrie.Brilla@wwu.edu or 360-650-3056.
Questions about your rights as a research subject should be directed to Janai Symons, the
WWU Research Compliance Officer (RCO), at Janai.Symons@wwu.edu or 360-650-3082. If
you experience injury or any adverse effect from this study, contact Kalee Larsen, Dr. Lorrie
Brilla, or Janai Symons.
All data collected will be kept completely confidential. The data will be stored on a
password protected computer and external hard drive and stored separately from the signed
consent forms. Data will be analyzed by subject number and only primary researchers will have
access to the records.
Your signature indicates that you have read and understand the information provided
above, that you willingly agree to participate, that you may withdraw your consent at any time
and discontinue participation without penalty, that you have received a copy of this form, and
that you are not waiving any legal claims, rights, or remedies. Thank you for your participation
in this study.

__________________________________________________

_____/_____/_____

Participant’s Full Name (Printed)

Date

__________________________________________________
Participant’s Signature
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Physician Clearance Form

Participant’s Name: ____________________________________________________________
Have you read the consent form that describes the procedures for this program?
Yes or No
If not, please request a copy from the individual before authorizing clearance for
participation.

Physician Recommendations:
_____ Non-participation in the study
_____ Participation in the study with the following limitations and precautions related to
_____ the study:
Limitations:

Precautions:

_________________________________________
Physician’s Full Name (Printed)

__________________________________________
Physician’s Signature
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_____/_____/_____
Date

Health History Form

Name: ____________________________________________________________________
Date of Birth: _____________________________ Sex: _____________________________
Phone Number: _____________________________________________________________
Age: ___________

Emergency Contact Name: ____________________________________________________
Emergency Contact Phone Number: _____________________________________________

Please check if any of the following has happened to you, indicating the occurrence
Health Concerns:
Convulsions
Bowel problems
Digestions problems
Diabetes
Epilepsy
Ear infections
Eye trouble
Dizziness
Fainting
Frequent colds
Headaches
Heart trouble
Kidney trouble
Neuropathy
Sleep walking
Thyroid disorder
Other (please list)

If so, please date

Diseases:
Asthma
Bronchitis
Chicken pox
COPD
German measles
Mononucleosis
Measles
Mumps
Pneumonia
Poliomyelitis
Rheumatic Fever
Scarlet Fever
Tuberculosis

If so, please date

Allergies:
Hay fever
Insect stings
Penicillin

Please describe any drug allergies that you are aware of:
______________________________________________________________________________
______________________________________________________________________________
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Please describe any food allergies that you are aware of:
______________________________________________________________________________
______________________________________________________________________________
Have you or any of your immediate family suffered from: Tuberculosis, Mental Illness, Epilepsy,
Neuromuscular Disease, Nervous Breakdown, Heart Disease, Asthma, Diabetes, Lung Disease,
Other diseases? If “yes,” please describe:
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
List any operations, hospitalizations, serious injuries, and disabilities. Please include dates:
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
Please describe any other disease, physical limitations, or details of the above:
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
Please list any medications that you are presently taking:
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
How often do you exercise? How long do you exercise for? What type of exercises do you
partake in?
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________

100

How much sleep do you average in one night? Do you wake up feeling rested in the morning?
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
Do you smoke? If yes, please indicate the amount:
______________________________________________________________________________
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Appendix E.
Data Collection Checklist
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Data Collection Checklist
Setup
Turn computer on
Turn on Biopac Systems MP 1500
Log into Acknowledge 4.4
Prepare electrodes
Red wire plugged into VIN+
White wire plugged into VINBlack wire plugged into GRD
Make template using settings on ECG Box
Test (if time) to make sure equipment is working properly
Items to set out: razor, stop watch, table, WOMAC
Set up: Table, space to complete the WOMAC, chair for expiratory pause

WOMAC
Give the subject instructions for completing the WOMAC
Provide the subject with a #2 pencil
Allow subject time to complete the questionnaire
Check to make sure all questions have been completed
Mark the WOMAC with the subject’s #
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Heart Rate Variability
Prepare skin by shaving and using an alcohol swab on inside of R wrist and inside of
L and R ankles about 1 inch above the ankle
Remove sticker from electrodes and place at R wrist and R and L ankle sites
Instruct subject to lay on table
Connect white wire to R wrist
Connect red wire to L ankle
Connect black wire to R ankle
Allow subject to lie on table while instructions are given
Inform subject that HRV will be taken for 5 minutes
Instruct subject to lie completely still: No moving or talking or they will have to start
over
Select “Start”
Record for 5 minutes
Select “Stop”
Select “Analysis”
Select “Heart rate variability”
Select output: interpolated tachogram, paste results to journal, and show spectrum
Select OK
Record variables for HRV on data collection sheet
Copy and paste values to excel sheet
Save HRV template
Remove wires and electrodes from subject and allow them to rise slowly
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Expiratory Pause
Have subject sit in a chair
Back straight and feet flat on the floor
Instruct subject to breathe normally
Instruct subject that they will practice the expiratory pause first
Demonstrate the expiratory pause for them
Practice the pause with them
Breathe in normally
Breathe out normally
Plug your nose and close your mouth
Hold your breath until the very first urge to breathe
Then open your mouth and breathe in
For measurement:
Obtain stopwatch
When subject is ready:
Breathe in normally
Breathe out normally
Plug your nose, close your mouth, and hold
Record time until subject opens mouth
Repeat 3 times and record
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Before Subject Leaves
WOMAC completed
HRV: LF, HF, and LF/HF ratio recorded
3 expiratory pauses recorded
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Appendix F.
Data Collection Sheet
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Subject #:______
Pre-Test

WOMAC
_____ WOMAC completed and attached to this sheet

Heart Rate Variability
Power in VLF band: ____________________________s2
Power in LF band: _____________________________s2
Power in HF band: _____________________________s2
Power in VHF band: ____________________________s2
Sympathetic: ___________________________________
Vagal: ________________________________________
Sympathetic/Vagal Ratio:_________________________

Expiratory Pause
Trial one: _____________________________________
Trial two: _____________________________________
Trial three: ____________________________________
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Subject #:______
Post-Test

WOMAC
_____ WOMAC completed and attached to this sheet

Heart Rate Variability
Power in VLF band: ____________________________s2
Power in LF band: _____________________________s2
Power in HF band: _____________________________s2
Power in VHF band: ____________________________s2
Sympathetic: ___________________________________
Vagal: ________________________________________
Sympathetic/Vagal Ratio:_________________________

Expiratory Pause
Trial one: _____________________________________
Trial two: _____________________________________
Trial three: ____________________________________
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Appendix G.
Raw Data
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Subject Characteristics
Training
Age (years)
59
67
62
66
70
69
54
58
81
79

Height (m)
1.7
1.7
1.6
1.7
1.7
1.7
1.6
1.6
1.6
1.6

Weight (kg)
70.8
68.0
60.8
63.5
64.9
106.1
72.6
72.6
70.3
55.8

Height (m)
1.8
1.6
1.7
1.8
1.8
1.6
1.5
1.7
1.7
1.8

Weight (kg)
83.9
59.0
58.1
88.5
83.9
72.6
63.5
61.2
95.3
72.6

Control
Age (years)
20
79
47
47
27
62
25
57
54
64

WOMAC VAS Pain and Physical Function
Training
ID #
1
2
3
6
7
9
10
11
12
17

Pain
Pre
113
292
248
19
112
218
136
230
32
83

Post
9
270
136
57
24
28
27
201
54
37

Change
-104
-22
-112
+38
-88
-190
-109
-29
+22
-46
111

Physical Function
Pre
Post
192
28
285
383
1042
846
271
106
453
123
363
34
238
97
742
692
272
336
483
115

Change
-164
+98
-196
-166
-330
-329
-141
-50
+65
-368

Control
ID #
4
5
8
14
14
15
16
18
119
20

Pain
Pre
78
129
62
59
260
303
111
87
80
60

Post
53
91
76
73
235
202
99
57
33
3

Change
-25
-38
+15
+14
-25
-102
-12
-30
-48
-57

Physical Function
Pre
Post
254
225
659
368
175
203
441
365
916
830
1206
804
240
246
353
236
425
55
153
47

Change
-29
-292
+29
-76
-86
-403
+6
-117
-370
-107

Heart Rate Variability: LF, HF, and LF/HF Ratio
Training
ID #
1
2
3
6
7
9
10
11
12
17

LF Power (ms2)
Pre
Post
1779.1 0.0260
0.0345 0.0241
2.1444 0.4112
0.1558 0.0666
1.2412 0.1853
4.4264 91.818
5.6701 0.2654
0.1465 3.8865
0.0108 0.0094
0.0498 1.4710

HF Power (ms2)
Change Pre
Post
-1779
127.11 0.0423
-0.0104 0.0173 0.0482
-1.733
1.9859 0.4939
+0.0892 0.0049 0.0053
-1.056
2.9097 0.4254
+87.39 5.2230 61.614
-5.405
2.9049 0.1054
+3.740 0.2178 3.9493
-0.0014 0.0038 0.0100
+1.421 0.0605 3.4958

LF/HF Ratio
Change Pre
Post
-127.1
13.997 0.6140
+0.0309 1.9978 0.5002
-1.492
1.0797 0.8325
+0.0004 31.764 12.555
-2.484
0.4266 0.4356
+56.39 0.8474 1.4902
-2.799
1.9519 2.5174
+3.731 0.6724 0.9841
+0.0062 2.8427 0.9380
+3.435 0.8222 0.4208

Change
-13.38
-1.498
-0.2473
-19.21
+0.0090
+0.6427
+0.5654
+0.3117
-1.905
-.4014

LF Power (ms2)
Pre
Post
4.9232 0.4258
1.1892 0.3958
196.68 0.8059
76.896 1.9612
0.0953 0.1105
0.2806 0.5358
8.5086 0.2983
0.0523 1.9893
0.1103 0.1094

HF Power (ms2)
Change Pre
Post
-4.4973 18.370 1.0183
-0.7934 0.9354 0.4494
-195.87 16.030 2.1798
-74.934 25.814 5.1668
+0.0152 0.1440 0.1566
+0.2552 0.4188 0.4032
-8.2103 4.9739 0.1506
+1.9370 0.0777 3.9233
-0.0009 0.1166 0.0510

LF/HF Ratio
Change Pre
Post
-17.352 0.2680 0.4182
-0.4860 1.2714 0.8807
-13.851 12.270 0.3697
-20.647 2.9789 0.3796
+0.0126 0.6619 0.7056
-0.0156 0.6700 1.3289
-4.8232 1.7107 1.9802
+3.8456 0.6730 0.5070
-0.0656 0.9465 2.1466

Change
+0.1502
-0.3906
-11.900
-2.5993
+0.0437
+0.6589
+0.2696
-0.1660
+1.2001

Control
ID #
4
5
8
13
15
16
18
19
20
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Expiratory Pause
Training
ID #
1
2
3
6
7
9
10
11
12
17

Pre
23
5
28
26
7
36
30
35
11
11

Post
17
25
6
32
10
29
32
31
27
23

Change
-6
+20
-22
+6
+3
-7
+2
-4
+16
+12

Pre
33
25
42
28
18
21
33
13
34
10

Post
22
34
36
33
19
21
32
18
23
13

Change
-11
+9
-6
+5
+1
0
-1
+5
-11
+3

Control
ID #
4
5
8
13
14
15
16
18
19
20

Training Group Breathing Logs
At-home breathing (minutes)
ID #
Week 1
Week 2
1
100
100
2
130
130
3
150
150
6
100
110
7
120
135
9
75
142
10
100
100
11
-130
12
90
106
17
105
150

Week 3
100
150
150
110
130
130
100
-100
150
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Week 4
100
150
150
110
130
120
100
100
100
150

Week 5
100
150
150
82
130
123
100
-100
150

Week 6
100
150
150
160
130
97
100
150
100
150

Diet and Exercise Logs
Training

ID #
1
3
6
7
9
10
11
19

Diet (kcal in)
Pre
3201.98
1170.19
1666.97
1873.92
1241.62
2931.56
1172.84
1097.80

Post
2982.56
936.38
1409.14
883.36
1430.05
3115.75
1792.02
1291.20

Exercise (kcal out)
Pre
Post
45.82
50.41
39.08
45.98
53.22
52.33
49.23
45.81
45.83
48.79
53.84
50.82
40.44
42.46
57.81
55.81

Diet (kcal in)
Pre
2085.84
1123.36
2513.25
1401.73
1318.84
2865.45

Post
2100.75
1396.12
2615.32
1605.75
1265.75
2670.85

Exercise (kcal out)
Pre
Post
50.51
53.43
55.64
50.46
45.95
49.87
39.68
43.26
71.84
79.71
42.16
38.12

Control

ID #
4
5
13
15
18
19
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Appendix H.
IBM SPSS Statistical Output
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WOMAC VAS Pain
Descriptive Statistics
Std.
Group
Mean
Deviation
PainPre Training
148.00
94.062
Control
122.60
87.252
Total
135.30
89.258
PainPost Training
84.10
88.570
Control
91.90
72.543
Total

88.00

N
10
10
20
10
10

78.897

20

Mauchly's Test of Sphericitya
Measure: Pain
Within Subjects
Effect
test

Mauchly' Approx.
sW
Chi-Square
1.000
.000

df
0

Epsilonb
Greenhous HuynhSig.
e-Geisser
Feldt
.
1.000
1.000

Lowerbound
1.000

Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed
dependent variables is proportional to an identity matrix.
a. Design: Intercept + Group
Within Subjects Design: test
b. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected
tests are displayed in the Tests of Within-Subjects Effects table.
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Tests of Within-Subjects Effects
Measure: Pain
Type III
Sum of
Source
Squares
test
Sphericity
22372.9
Assumed
00
Greenhouse- 22372.9
Geisser
00
Huynh-Feldt 22372.9
00
Lower-bound 22372.9
00
test *
Sphericity
2755.60
Group Assumed
0
Greenhouse- 2755.60
Geisser
0
Huynh-Feldt 2755.60
0
Lower-bound 2755.60
0
Error(t Sphericity
26919.0
est)
Assumed
00
Greenhouse- 26919.0
Geisser
00
Huynh-Feldt 26919.0
00
Lower-bound 26919.0
00
a. Computed using alpha = .025

df
1
1.000
1.000
1.000
1
1.000
1.000
1.000
18
18.00
0
18.00
0
18.00
0

Mean
Square
22372.9
00
22372.9
00
22372.9
00
22372.9
00
2755.60
0
2755.60
0
2755.60
0
2755.60
0
1495.50
0
1495.50
0
1495.50
0
1495.50
0
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F
Sig.
14.96
.001
0
14.96
.001
0
14.96
.001
0
14.96
.001
0

Partial Noncent.
Eta
Paramet Observe
Squared
er
d Powera
.454

14.960

.911

.454

14.960

.911

.454

14.960

.911

.454

14.960

.911

1.843

.191

.093

1.843

.165

1.843

.191

.093

1.843

.165

1.843

.191

.093

1.843

.165

1.843

.191

.093

1.843

.165

Tests of Between-Subjects Effects
Measure: Pain
Transformed Variable: Average
Type III
Sum of
Mean
Source Squares
df
Square
F
Interce 498628.90
498628.90
1
37.524
pt
0
0
Group
774.400
1
774.400
.058
Error
239190.70
18 13288.372
0
a. Computed using alpha = .025
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Partial Eta
Squared

Noncent.
Parameter

.000

.676

37.524

1.000

.812

.003

.058

.029

Sig.

Observed
Powera

WOMAC VAS Physical Function
Descriptive Statistics

FunctionPre

Group
Training

Mean

Std. Deviation

N

433.85

267.529

10

Control

482.00

346.202

10

Total

457.93

302.136

20

275.85

287.362

10

337.70

273.936

10

306.77

275.078

20

FunctionPost Training
Control
Total

Mauchly's Test of Sphericitya
Measure: Function
Epsilonb
Approx.
Within Subjects Mauchly'
ChiGreenhous HuynhLowerEffect
sW
Square
df
Sig.
e-Geisser
Feldt
bound
test
1.000
.000
0
.
1.000
1.000
1.000
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed
dependent variables is proportional to an identity matrix.
a. Design: Intercept + Group
Within Subjects Design: test
b. May be used to adjust the degrees of freedom for the averaged tests of significance.
Corrected tests are displayed in the Tests of Within-Subjects Effects table.
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Tests of Within-Subjects Effects
Measure: Function
Type III
Sum of
Mean
Source
Squares df
Square
F
Sig.
test
Sphericity
228463.
228463. 18.42
1
.000
Assumed
225
225
5
Greenhouse- 228463.
228463. 18.42
1.000
.000
Geisser
225
225
5
Huynh-Feldt
Lowerbound
test * Sphericity
Group Assumed
GreenhouseGeisser
Huynh-Feldt
Lowerbound
Error(t Sphericity
est)
Assumed
GreenhouseGeisser
Huynh-Feldt
Lowerbound

228463.
228463. 18.42
1.000
225
225
5
228463.
228463. 18.42
1.000
225
225
5
469.225

Noncent
Partial
.
Observe
Eta
Paramet
d
Squared
er
Powera
.506

18.425

.959

.506

18.425

.959

.000

.506

18.425

.959

.000

.506

18.425

.959

1 469.225

.038

.848

.002

.038

.027

469.225 1.000 469.225

.038

.848

.002

.038

.027

469.225 1.000 469.225

.038

.848

.002

.038

.027

469.225 1.000 469.225

.038

.848

.002

.038

.027

223192.
12399.5
18
550
86
223192. 18.00 12399.5
550
0
86
223192. 18.00 12399.5
550
0
86
223192. 18.00 12399.5
550
0
86

a. Computed using alpha = .025
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Tests of Between-Subjects Effects
Measure: Function
Transformed Variable: Average
Type III
Sum of
Mean
Source Squares
df
Square
F
Interce 5847660.9
5847660.
1
36.069
pt
00
900
Group
30250.00
30250.000
1
.187
0
Error
2918213.1
162122.9
18
00
50
a. Computed using alpha = .025
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Sig.

Partial Eta Noncent.
Squared Parameter

Observed
Powera

.000

.667

36.069

1.000

.671

.010

.187

.037

WOMAC VAS Pain Change Score
Descriptive Statistics
Dependent Variable: PainChange
Std.
Group
Mean
Deviation
Trainin
-63.90
69.447
g
Control
-30.70
34.045
Total
-47.30
55.890

N
10
10
20

Tests of Between-Subjects Effects
Dependent Variable: PainChange
Type III Sum
Mean
Source
of Squares
df
Square
F
Corrected
5511.200a
1
5511.200
1.843
Model
Intercept
44745.800
1
44745.800 14.960
Group
5511.200
1
5511.200
1.843
Error
53838.000
18
2991.000
Total
104095.000
20
Corrected
59349.200
19
Total
a. R Squared = .093 (Adjusted R Squared = .042)

Estimates
Dependent Variable: PainChange
97.5% Confidence Interval
Group
Trainin
g
Control

Mean

Std.
Error

Lower
Bound

Upper
Bound

-63.900

17.295

-106.185

-21.615

-30.700

17.295

-72.985

11.585
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Sig.

Partial Eta
Squared

.191

.093

.001
.191

.454
.093

Pairwise Comparisons
Dependent Variable: PainChange
97.5% Confidence Interval
Mean
for Differencea
(I)
Difference
Std.
Group
(J) Group
(I-J)
Error
Sig.a Lower Bound Upper Bound
Training Control
-33.200
24.458
.191
-93.000
26.600
Control Training
33.200
24.458
.191
-26.600
93.000
Based on estimated marginal means
a. Adjustment for multiple comparisons: Bonferroni.

Univariate Tests
Dependent Variable: PainChange
Sum of
Mean
Partial Eta
Squares
df
Square
F
Sig.
Squared
Contrast
5511.200
1
5511.200
1.843
.191
.093
Error
53838.000
18
2991.000
The F tests the effect of Group. This test is based on the linearly independent
pairwise comparisons among the estimated marginal means.

WOMAC VAS Physical Function Change Score
Descriptive Statistics
Dependent Variable: FuncChange
Std.
Group
Mean
Deviation
Trainin
-158.00
160.235
g
Control
-144.35
154.650
Total
-151.17
153.427

N
10
10
20
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Tests of Between-Subjects Effects
Dependent Variable: FuncChange
Type III Sum
Mean
Source
of Squares
df
Square
F
Corrected
931.613a
1
931.613
.038
Model
Intercept
457077.613
1 457077.613 18.434
Group
931.613
1
931.613
.038
Error
446326.525
18
24795.918
Total
904335.750
20
Corrected
447258.138
19
Total
a. R Squared = .002 (Adjusted R Squared = -.053)

Sig.

Partial Eta
Squared

.848

.002

.000
.848

.506
.002

Estimates
Dependent Variable: FuncChange
97.5% Confidence Interval
Std.
Lower
Upper
Group
Mean
Error
Bound
Bound
Trainin
g
Control

-158.000

49.795

-279.750

-36.250

-144.350

49.795

-266.100

-22.600

Pairwise Comparisons
Dependent Variable: FuncChange
(I)
Group

(J) Group

Mean
Difference
(I-J)

Std.
Error

Sig.a

Training Control
-13.650
70.421
.848
Control Training
13.650
70.421
.848
Based on estimated marginal means
a. Adjustment for multiple comparisons: Bonferroni.
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97.5% Confidence Interval
for Differencea
Lower Bound Upper Bound
-185.831
-158.531

158.531
185.831

Univariate Tests
Dependent Variable: FuncChange
Sum of
Mean
Partial Eta
Squares
df
Square
F
Sig.
Squared
Contrast
931.613
1
931.613
.038
.848
.002
Error
446326.525
18
24795.918
The F tests the effect of Group. This test is based on the linearly independent
pairwise comparisons among the estimated marginal means.

LF Power
Descriptive Statistics
Std.
Group
Mean
Deviation
LFPre Training 179.30193 562.129408
Control
32.08216
66.551066
Total
109.56625 407.021860
LFPost Training
9.81471
28.831941
Control
Total

.73689
5.51469

N
10
9
19
10

.733494
20.918066

9
19
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Mauchly's Test of Sphericitya
Measure: LF
Epsilonb

Within Subjects
Effect
test

Mauchly' Approx.
sW
Chi-Square
1.000

.000

df

Greenhous
e-Geisser

Sig.
0

.

1.000

HuynhFeldt
1.000

Lowerbound
1.000

Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed
dependent variables is proportional to an identity matrix.

a. Design: Intercept + Group
Within Subjects Design: test

b. May be used to adjust the degrees of freedom for the averaged tests of significance.
Corrected tests are displayed in the Tests of Within-Subjects Effects table.
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Tests of Within-Subjects Effects
Measure: LF
Type III
Sum of
Source
Squares
df
test
Sphericity
95527.1
1
Assumed
61
Greenhouse- 95527.1
1.000
Geisser
61
Huynh-Feldt 95527.1
1.000
61
Lower-bound 95527.1
1.000
61
test *
Sphericity
45197.0
1
Group Assumed
52
Greenhouse- 45197.0
1.000
Geisser
52
Huynh-Feldt 45197.0
1.000
52
Lower-bound 45197.0
1.000
52
Error(t Sphericity
1460451
17
est)
Assumed
.875
Greenhouse- 1460451 17.00
Geisser
.875
0
Huynh-Feldt 1460451 17.00
.875
0
Lower-bound 1460451 17.00
.875
0
a. Computed using alpha = .016667

Mean
Square
95527.1
61
95527.1
61
95527.1
61
95527.1
61
45197.0
52
45197.0
52
45197.0
52
45197.0
52
85908.9
34
85908.9
34
85908.9
34
85908.9
34
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F

Sig.

Partial Noncent.
Eta
Paramet Observe
Squared
er
d Powera

1.112

.306

.061

1.112

.077

1.112

.306

.061

1.112

.077

1.112

.306

.061

1.112

.077

1.112

.306

.061

1.112

.077

.526

.478

.030

.526

.043

.526

.478

.030

.526

.043

.526

.478

.030

.526

.043

.526

.478

.030

.526

.043

Tests of Between-Subjects Effects
Measure: LF
Transformed Variable: Average
Type III
Sum of
Mean
Source
Squares
df
Square
Interce 116657.65
116657.65
1
pt
4
4
Group 57858.002
1 57858.002
Error

1426371.5
55

F

Sig.

Partial Eta
Squared

Noncent.
Parameter

Observed
Powera

1.390

.255

.076

1.390

.095

.690

.418

.039

.690

.052

17 83904.209

a. Computed using alpha = .016667
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HF Power
Descriptive Statistics
Std.
Group
Mean
Deviation
HFPre Training 14.04388
39.767491
Control
7.43114
9.934835
Total
10.91153
29.087819
HFPost Training 7.01798
19.236342
Control
1.49989
1.872291
Total

4.40415

N
10
9
19
10
9

13.949531

19

Mauchly's Test of Sphericitya
Measure: HF
Epsilonb
Within Subjects
Effect
test

Mauchly' Approx.
sW
Chi-Square
1.000
.000

df
0

Greenhous
Sig.
e-Geisser
.
1.000

HuynhFeldt
1.000

Lowerbound
1.000

Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed
dependent variables is proportional to an identity matrix.
a. Design: Intercept + Group
Within Subjects Design: test
b. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected
tests are displayed in the Tests of Within-Subjects Effects table.
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Tests of Within-Subjects Effects
Measure: HF

Source
test
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt

test *
Group

Lowerbound
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt

Lowerbound
Error(t Sphericity
est)
Assumed
GreenhouseGeisser
Huynh-Feldt

Type III
Sum of
Squares

Mean
Square

F

Sig.

1 397.629

.693

.417

.039

.693

.052

397.629 1.000 397.629

.693

.417

.039

.693

.052

397.629 1.000 397.629

.693

.417

.039

.693

.052

397.629 1.000 397.629

.693

.417

.039

.693

.052

397.629

2.838

df

Partial Noncent.
Eta
Paramet Observe
Squared
er
d Powera

1

2.838

.005

.945

.000

.005

.017

2.838 1.000

2.838

.005

.945

.000

.005

.017

2.838 1.000

2.838

.005

.945

.000

.005

.017

2.838 1.000

2.838

.005

.945

.000

.005

.017

9757.03
17
9
9757.03 17.00
9
0
9757.03 17.00
9
0
Lower9757.03 17.00
bound
9
0
a. Computed using alpha = .016667

573.943
573.943
573.943
573.943
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Tests of Between-Subjects Effects
Measure: HF
Transformed Variable: Average
Type III
Sum of
Mean
Source Squares
df
Square
Interce
2130.568
1 2130.568
pt
Group
348.530
1
348.530
Error
8624.025
17
507.296

F

Sig.

Partial Eta Noncent.
Squared Parameter

Observed
Powera

4.200

.056

.198

4.200

.303

.687

.419

.039

.687

.052

a. Computed using alpha = .016667
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LF/HF Ratio
Descriptive Statistics
Std.
Group
Mean
Deviation
RatioPre Training 5.64018
10.032318
Control 2.38331
3.793797
Total
4.09745
7.714396
RatioPost Training 2.12875
3.717831
Control
.96851
.692760
Total

1.57916

N
10
9
19
10
9

2.734718

19

Mauchly's Test of Sphericitya
Measure: Ratio

Within Subjects Mauchly'
Effect
sW
test
1.000

Approx.
ChiSquare
.000

Epsilonb
df

Greenhous
e-Geisser

Sig.
0

.

1.000

HuynhFeldt

Lowerbound

1.000

1.000

Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed
dependent variables is proportional to an identity matrix.
a. Design: Intercept + Group
Within Subjects Design: test
b. May be used to adjust the degrees of freedom for the averaged tests of significance.
Corrected tests are displayed in the Tests of Within-Subjects Effects table.
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Tests of Within-Subjects Effects
Measure: Ratio

Source
test
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt

test *
Group

Lowerbound
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt

Lowerbound
Error(t Sphericity
est)
Assumed
GreenhouseGeisser
Huynh-Feldt

Type III
Sum of
Squares
57.476

Mean
Square

df

F

Sig.

Noncent
Partial
.
Observe
Eta
Paramet
d
Squared
er
Powera

1

57.476 3.464

.080

.169

3.464

.246

57.476 1.000

57.476 3.464

.080

.169

3.464

.246

57.476 1.000

57.476 3.464

.080

.169

3.464

.246

57.476 1.000

57.476 3.464

.080

.169

3.464

.246

10.411

1

10.411

.627

.439

.036

.627

.049

10.411 1.000

10.411

.627

.439

.036

.627

.049

10.411 1.000

10.411

.627

.439

.036

.627

.049

10.411 1.000

10.411

.627

.439

.036

.627

.049

282.107

17

17.00
0
17.00
282.107
0
Lower17.00
282.107
bound
0
a. Computed using alpha = .016667
282.107

16.595
16.595
16.595
16.595
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Tests of Between-Subjects Effects
Measure: Ratio
Transformed Variable: Average
Type III
Sum of
Mean
Source Squares
df
Square
Interce
292.905
1
292.905
pt
Group
46.210
1
46.210
Error
867.102
17
51.006

F

Sig.

Partial Eta Noncent.
Squared Parameter

Observed
Powera

5.743

.028

.253

5.743

.421

.906

.355

.051

.906

.065

a. Computed using alpha = .016667
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Expiratory Pause
Descriptive Statistics
Std.
Group
Mean
Deviation
PausePre Training
21.20
11.698
Control
25.60
10.211
Total
23.40
10.923
PausePost Training
23.20
9.283
Control
25.10
7.978
Total

24.15

N
10
10
20
10
10

8.481

20

Mauchly's Test of Sphericitya
Measure: Pause
Epsilonb

Within Subjects Mauchly'
Effect
sW
test
1.000

Approx.
ChiSquare
.000

df

Greenhous
e-Geisser

Sig.
0

.

1.000

HuynhFeldt

Lowerbound

1.000

1.000

Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed
dependent variables is proportional to an identity matrix.

a. Design: Intercept + Group
Within Subjects Design: test

b. May be used to adjust the degrees of freedom for the averaged tests of significance.
Corrected tests are displayed in the Tests of Within-Subjects Effects table.
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Tests of Within-Subjects Effects
Measure: Pause

Source
test
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt

test *
Group

Lowerbound
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt

Lowerbound
Error(t Sphericity
est)
Assumed
GreenhouseGeisser
Huynh-Feldt

Type III
Sum of
Squares
5.625

Mean
Square

df

F

Sig.

Noncent
Partial
.
Observe
Eta
Paramet
d
Squared
er
Powera

1

5.625

.111

.743

.006

.111

.061

5.625 1.000

5.625

.111

.743

.006

.111

.061

5.625 1.000

5.625

.111

.743

.006

.111

.061

5.625 1.000

5.625

.111

.743

.006

.111

.061

1

15.625

.307

.586

.017

.307

.082

15.625 1.000

15.625

.307

.586

.017

.307

.082

15.625 1.000

15.625

.307

.586

.017

.307

.082

15.625 1.000

15.625

.307

.586

.017

.307

.082

15.625

915.250

18

18.00
0
18.00
915.250
0
Lower18.00
915.250
bound
0
a. Computed using alpha = .05
915.250

50.847
50.847
50.847
50.847
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Tests of Between-Subjects Effects
Measure: Pause
Transformed Variable: Average
Type III
Sum of
Mean
Source Squares
df
Square
F
Interce
156.33
22610.025
1 22610.025
pt
6
Group
99.225
1
99.225
.686
Error
2603.250
18
144.625
a. Computed using alpha = .05
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Sig.

Partial Eta Noncent.
Squared Parameter

Observed
Powera

.000

.897

156.336

1.000

.418

.037

.686

.123

Expiratory Pause Change Score

Univariate Analysis of Variance
Between-Subjects Factors
Value
Label
N
Group 1
Training
10
2
Control
10

Descriptive Statistics
Dependent Variable: PauseChange
Std.
Group
Mean
Deviation
Training
2.0000
12.44544
Control
-.6000
6.80196
Total
.7000
9.85206

N
10
10
20

Levene's Test of Equality of Error
Variancesa
Dependent Variable: PauseChange
F
df1
df2
Sig.
2.327
1
18
.145
Tests the null hypothesis that the error
variance of the dependent variable is equal
across groups.
a. Design: Intercept + Group
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Tests of Between-Subjects Effects
Dependent Variable: PauseChange
Type III Sum
Source
of Squares
df
Mean Square
F
Corrected
33.800a
1
33.800
.336
Model
Intercept
9.800
1
9.800
.097
Group
33.800
1
33.800
.336
Error
1810.400
18
100.578
Total
1854.000
20
Corrected Total
1844.200
19
a. R Squared = .018 (Adjusted R Squared = -.036)

Sig.

Partial Eta
Squared

.569

.018

.759
.569

.005
.018

Estimated Marginal Means
Group
Estimates
Dependent Variable: PauseChange
95% Confidence Interval
Group
Training
Control

Mean Std. Error
2.000
3.171
-.600
3.171

Lower
Bound
-4.663
-7.263

Upper
Bound
8.663
6.063

Pairwise Comparisons
Dependent Variable: PauseChange
95% Confidence Interval for
Mean
Differencea
(I)
Difference (IGroup
(J) Group
J)
Std. Error
Sig.a
Lower Bound Upper Bound
Training Control
2.600
4.485
.569
-6.823
12.023
Control Training
-2.600
4.485
.569
-12.023
6.823
Based on estimated marginal means
a. Adjustment for multiple comparisons: Bonferroni.
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Univariate Tests
Dependent Variable: PauseChange
Sum of
Partial Eta
Squares
df
Mean Square
F
Sig.
Squared
Contrast
33.800
1
33.800
.336
.569
.018
Error
1810.400
18
100.578
The F tests the effect of Group. This test is based on the linearly independent pairwise
comparisons among the estimated marginal means.
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